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A. Background and rationale for this study 
 
 
1. The extracellular matrix: more than a scaffold 
 
The extracellular matrix (ECM) forms a complex microenvironment in the 
extracellular space and is critical for development, tissue structure, and cellular 
response.  The ECM consists of a myriad of proteins, glycoproteins, and 
proteoglycans that form a cross-linked scaffold that surrounds cells in all solid 
organs (1).  These fibrous proteins are produced by cells (i.e., fibroblasts) and, 
upon secretion into the extracellular environment, crosslink together to create a 
meshwork that serves as a scaffold for cells and that provides structure to tissue.  
The collagen scaffold to which glycoproteins and proteoglycans adhere is the 
main characteristic shared by the ECM of the basement membranes and 
interstitial matrices, regardless of physiological domain (1).  Physical changes to 
the extracellular landscape, including changes in ECM topography, crosslinking, 
and biochemistry, can affect cell migration, adhesion, and activation (2).  In 
addition to their role as structural compounds, these proteins can also serve as 
signaling molecules.  Indeed, ECM proteins are ligands of cell surface receptors, 
including integrins, which bind specific ECM matrix protein domains (e.g., the 
RGD motif).  The ECM also contributes to cell signaling by binding soluble 
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signaling molecules including cytokines, chemokines, and growth factors to 
create signaling gradients required for tissue development and migration of 
inflammatory cells during acute inflammation (3).   
Proteases and protease inhibitors comprise another group of proteins 
critical in the extracellular space.  These enzymes play an important role in the 
homeostasis of the extracellular environment and contribute to ECM remodeling 
in disease states (4).  Proteases may enhance the deposition of proteins to the 
ECM (e.g., proteases involved in the complement and coagulation cascades).  
Proteases can also break down matrix components to allow for rapid changes in 
the ECM organization, such as matrix metalloproteinases (MMPS), a disintegrin 
and metalloproteinase with thrombospondin motifs (ADAMTS), and other serine 
proteases.  The effects of ECM degradation by proteases modify both the 
physical and biochemical environment of the extracellular space.  For example, 
physical dissolution of the ECM by proteases can create space through which 
cells can migrate (5).  Alternatively, cleavage of ECM proteins by proteases can 
alter cell-ECM interactions by exposing/removing cryptic binding sites; for 
example, proteolysis of laminin-5 reveals integrin-binding sites which are critical 
for cell adhesion (6).  Proteases can also contribute to ECM dynamics by 
modulating the activity of other enzymes (e.g., proteinase precursors (7) and 
soluble mediators (e.g., IL-8, (2)).  Because of the wide-reaching effects of 
proteases, their activity is regulated and maintained via complex, often 
redundant, mechanisms.  Indeed, in addition to regulation of rates of synthesis 
and secretion, extracellular proteases frequently require activation, often via 
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cleavage by another protease, and conversely can be inhibited by endogenous 
inhibitors such as tissue inhibitors of matrix metalloproteinases (TIMPs) (5).   
 
2. The role of the ECM in inflammation and disease. 
Tight regulation of the ECM composition is necessary for normal tissue 
homeostasis, and dysregulation is often a hallmark in tissue pathology.  
Therefore, the organization, composition, and orientation of the ECM are 
controlled via multiple mechanisms including protein synthesis, modification, 
excretion, crosslinking, and enzymatic degradation.  Such tight regulation on so 
many levels also permits rapid changes in the ECM that allow it to play a 
dynamic and responsive role during inflammation and tissue repair.  
Perturbations in the ECM during either of these physiological states can 
contribute to disease initiation and development.   
During an acute inflammatory response, the ECM plays a pivotal role by 
serving as a structural barrier and chemokine reservoir, thereby regulating 
inflammatory cell migration.  Indeed, studies have shown that neutrophil 
transmigration is greater through vascular areas with lower ECM concentration 
(8).  Additionally, ECM binding of cytokines, including IL-2, TNFα, TGFβ, and 
RANTES (9-11), have been shown to regulate cell activation, adhesion, and 
migration.  The interaction between the ECM and cell infiltration is bidirectional - 
as leukocytes integrate structural and biochemical signals from the ECM, they in 
turn release matrix-degrading proteases (12) which alter the extracellular 
composition and allow for easier cell migration.   
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In the setting of chronic inflammation, dysregulation of ECM composition can 
lead to pathological tissue remodeling and, if not resolved, disease states 
including hepatic (13, 14) and pulmonary fibrosis (15-17), atherosclerosis (18, 
19) and cancer (20, 21).  Initiation of these disease states can occur via 
dysregulation at the level of ECM synthesis and/or degradation, leading to 
altered matrix accumulation and modification.  For example hepatic fibrosis is 
characterized by a robust increase in collagen Iα1 secretion by hepatic stellate 
cells (HSCs) (22) combined with a concomitant increase in crosslinking and a 
decrease in enzymatic degradation (23).  Such dynamic changes in extracellular 
composition can initiate and perpetuate disease via a variety of mechanisms 
including altered tissue biomechanics (i.e. tissue stiffness) (24, 25), increased 
integrin-mediated cell adhesion (26) and activation of immune cells (27). 
 
3. Statement of goals 
The role of tissue remodeling in advanced stages of liver disease, including 
fibrosis, is clear.  Indeed, the major macroscopic change in hepatic fibrogenesis 
is characterized by severe collagen deposition and scarring.  Currently, hepatic 
fibrosis is generally considered irreversible, and there is currently no FDA-
approved therapy to halt or reverse liver fibrosis.  Recent studies have shown 
that transitional tissue remodeling may occur during inflammatory liver disease, 
before the development of fibrosis (28).  Additionally, protecting against these 
subtle changes can protect against liver injury and inflammation (29).  These 
findings suggest that targeting the ECM in earlier stages of liver disease could 
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provide therapeutic benefit by preventing disease progression to later, 
irreversible stages of fibrosis.  The goal of this dissertation is to examine the role 
of transitional tissue remodeling in fatty liver disease.  Furthermore, it aims to 
identify new extracellular matrix proteins that play a role in early stages of 
remodeling which could serve as novel therapeutic targets.   
 
4. Natural history of liver disease 
The natural history of liver disease is well documented and encompasses a 
spectrum of disease states including earlier stages of fatty liver disease such as 
steatosis, steatohepatitis, and later stages of disease including fibrosis and 
cirrhosis (30, 31).  The earliest stage of liver disease, simple steatosis, is 
characterized by micro- and macro-vesicular fat accumulation and is generally 
considered reversible if appropriate changes to the lifestyle are made and 
maintained.  In the absence of lifestyle modifications, individuals may develop 
steatohepatitis, which is characterized by persistence of accumulated fat in 
addition to chronic hepatic inflammation (hepatitis).  Later stages of liver disease, 
including fibrosis and cirrhosis, are characterized by collagen deposition and 
regenerative nodules, respectively (31, 32).   
Despite the vast amount of money spent on treating alcoholic liver disease, 
therapeutic options remain limited to palliative care in the late stages of disease.  
Currently there is no FDA-approved therapy in existence to halt or reverse 
disease progression.  If a rational, targeted therapy is to be developed, currently 
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accepted mechanisms of disease progression must be better understood and 
new therapeutic targets identified.   
 
5. Alcoholic liver disease 
Alcohol is one of the most commonly recognized causes of liver disease.  
Alcoholic liver disease (ALD) affects more than 10 million Americans each year 
at a cost of more than $166 billion annually to treat the medical consequences of 
this disease (33).  After absorption from the small intestine, milli-molar 
concentrations of ethanol flow through the portal circulation and to the liver for 
degradation making the liver a prime target of ethanol toxicity.  During oxidative 
metabolism of alcohol in hepatocytes by alcohol dehydrogenase (ADH) and 
CYP2E1, a robust increase in the NADH/NAD+ ratio lends to a more reduced 
cellular environment.  This reduced microenvironment blocks the beta-oxidation 
of fatty acids in the liver and increases the esterification of fatty acids.  
Accumulation of excess fatty acids in the liver leads to storage of these lipids in 
lipid droplets known as steatosis, which is a hallmark of early liver disease.   
Steatosis develops in nearly all individuals who consume moderate 
amounts of alcohol, and for most people has no health consequences.  Indeed, 
at the organismal level, hepatic steatosis may be viewed as a protective 
mechanism, as it restricts plasma lipid levels from rising.  However chronic 
alcohol consumption can lead to development of later stages of liver disease, 
including alcoholic steatohepatitis (ASH) as well as fibrosis and cirrhosis.  These 
more severe stages of ALD develop in only a minority of chronic alcoholics.  One 
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explanation for this discrepancy is the 2-hit hypothesis, which suggests that 
progression from simple steatosis to later stages of liver disease requires 
multiple insults, or ‘hits’ (34, 35).  According to this paradigm, a first ‘hit,’ such as 
hepatic steatosis, sensitizes the liver to a second hit such as oxidative stress (36) 
or inflammatory cytokine signaling (37), both of which are also increased by 
ethanol consumption.   
 
6. Non-alcoholic fatty liver disease (NAFLD) 
Another common cause of fatty liver disease is obesity.  Obesity is a growing 
problem both nationally and globally, with statistics estimated that more than 78 
million U.S adults are clinically obese (38).  Obesity is associated with a myriad 
of health effects including metabolic syndrome, cardiovascular risks, and non-
alcoholic fatty liver disease (NAFLD).  It has been difficult to estimate the 
prevalence of NAFLD within populations and figures range depending on the 
cohort studied, however current estimates indicate that up to 19% of the 
American population may have some degree of NAFLD (39), with the highest 
prevalence of NAFLD among the morbidly obese (40).  Interestingly, despite a 
high prevalence of steatosis among obese individuals, it is estimated that less 
one third of patients with NAFLD will develop nonalcoholic steatohepatitis 
(NASH) (40-42), the more severe inflammatory stage of the disease.  Increased 
susceptibility to disease progression in some individuals is likely due to a variety 
of factors, including genetic predisposition, and environmental exposures (43).  
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Similar to ALD, it is hypothesized that multiple hits are required for the 
development of later stages of NAFLD (34, 43).   
Our lab is particularly interested in the enhanced susceptibility to liver injury 
caused by low levels of arsenic in the setting of NAFLD.  Arsenic is a natural 
contaminant of the drinking water and at very high concentrations has been 
shown to cause overt liver damage (44, 45).  Arsenic levels found in the United 
States are generally considered too low to cause toxicity, however even low 
levels of arsenic exposure have been linked to subtle hepatic changes including 
capillarization of sinusoidal endothelial cells, a type of remodeling response in 
the liver (46).  Moreover, low levels of arsenic have also been shown to sensitize 
the liver to inflammatory insult (47).  A previous study from our group has 
implicated an interaction between HFD and subhepatotoxic arsenic exposure, the 
combination of which caused enhanced liver injury.  These data support the 
hypothesis that HFD may sensitize the liver to otherwise innocuous toxins, 
including arsenic, resulting in progression of liver disease.  As will be 
demonstrated in this work, a key effect of arsenic appears to be to enhance the 
deposition of fibrin ECM in response to HFD. 
 
7. ECM in fatty liver disease  
As mentioned above, the major part of the study of the role of the ECM in liver 
disease has focused on the robust increase in collagen deposition which is a 
hallmark of hepatic fibrosis.  However, other studies have shown that other ECM 
components, including fibronectin, elastin, laminin and hyaluron, are also altered 
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during hepatic fibrogenesis (48).  Global changes in the distribution and 
concentration of many different ECM components likely contribute to pathological 
tissue remodeling and the progression of fibrogenesis.  
Recent studies suggest that transitional tissue remodeling may occur before 
fibrosis.  For example, Gillis et al showed that ethanol exposure increases the 
secretion of fibronectin, a structural component of the ECM, by hepatic stellate 
cells (HSCs) prior to their activation (28).  Since activated HSCs play a role in 
fibrogenesis, these results suggesting that fibronectin secretion is increased prior 
to fibrogenesis.  This group has also shown that enhanced LPS-induced fibrin 
accumulation caused by acute alcohol exposure is critical to liver injury and 
inflammation (29, 49, 50).  It is likely that there are changes in other ECM 
proteins contributing to hepatic inflammation.  In support of this possibility, a 
proteomic approach used by Lai et al showed that a myriad of ECM-associated 
proteins are dysregulated during hepatocarcinogenesis (51)  Applying this 
proteomics technique to changes in the hepatic ECM proteome could identify 
potential players in transitional tissue remodeling in early stages of fatty liver 
disease.  
 
8. Alcoholic lung phenotype 
It has been estimated that up to 190,000 people suffer from acute lung injury 
(ALI) annually in the United States (52).  The risk of developing more severe 
forms of ALI such as acute respiratory distress syndrome (ARDS), is significantly 
higher in chronic alcoholics (53).  Furthermore, a history of chronic alcohol 
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consumption has been shown to increase the risk of mortality in ARDS patients 
(54).  Subsequent rodent studies investigating the possible mechanisms 
underlying the detrimental effects of alcohol on the lung indicate that chronic 
alcohol may cause a myriad of pulmonary changes, coined the ‘alcoholic lung 
phenotype,’ including increased pro-inflammatory cytokine release (54-57), 
induction of oxidative stress (58), and tissue remodeling (59, 60).  The 
dysregulated inflammatory response caused by alcohol is dependent on both the 
amount and duration of alcohol consumption and is suspected to be a key player 
in alcohol-related lung dysfunction (61).  The exact mechanisms that result in the 
‘alcoholic lung phenotype’ remain unclear, but, if identified, would point to 
potential targets for intervention in alcohol-related lung dysfunction. 
 
9. Parallel mechanisms of injury in the liver and lung 
Currently, the effects of chronic ethanol exposure on the liver and lung are 
considered to be independent of each other and thus are often studied 
separately.  However, independent studies investigating the effects of ethanol on 
the liver and lung individually have revealed that similar mechanisms are at play 
in each organ and, more specifically, that these organs have similar responses to 
alcohol exposure.  For example, alcohol enhances LPS-induced organ damage 
in both the liver and lung (58, 62).  Additionally, oxidative stress, a well-known 
mediator of alcohol-induced liver injury (63) is also involved in increased 
susceptibility to lung injury caused by alcohol (64).  Furthermore, both organs 
possess resident macrophages that can play a critical role in dysregulated 
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inflammation after alcohol exposure (65) and both exhibit subtle changes in the 
composition of the extracellular matrix (ECM) following alcohol exposure.  The 
deleterious effects of tissue remodeling are well understood with regards to 
hepatic (66) and pulmonary fibrosis (67), however recent work from both this lab 
and Roman’s group have implicated more subtle ECM changes to be a key step 
in disease progression in the liver and lung, respectively.  Specifically, the 
Roman lab has shown that chronic alcohol exposure increases pulmonary 
fibronectin deposition via alterations in both expression and degradation of ECM 
components (68).  Similarly, our lab has shown that ethanol enhances increased 
hepatic fibrin deposition caused by LPS and that subsequent inflammatory 
damage to the liver is a direct effect of fibrin accumulation (29, 50, 69-71). 
 
10. The gut-liver-lung axis 
Chronic alcohol abuse can act as a first ‘hit’ that leads to alterations in tissue 
architecture without causing detectible organ damage.  This alcoholic first ‘hit’ 
can render the host susceptible to injury in the presence of a second stimulus, 
such as endotoxemia.  Circulating levels of endotoxin (i.e. LPS) are increased in 
chronic alcoholics due to changes in intestinal permeability caused by alcohol 
exposure.  This increase in circulating endotoxin appears to be a common 
second ‘hit’ that drives progression of liver and lung injury.  While the role of the 
gut:liver axis in alcohol induced liver disease is now well-established (72, 73), we 
propose that organ-organ interactions after alcohol exposure are not limited to 
the gut:liver axis but may also include the lung.  For example, more than 30 
12 
 
years ago one cohort study showed that end-stage liver disease increased 
mortality associated with ARDS from 40-60% to 100% (74), suggesting that liver 
injury may directly impact susceptibility to lung injury.  Other studies investigating 
the multi-organ effects of endotoxemia indicate that interaction between the liver 
and lung is not only likely, but may occur via LPS-induced mediators (75) 
including TNFα (76), an inflammatory cytokine markedly increased in both end-
stage liver patients (77) and experimental models of liver injury.  The role of 
TNFα in pulmonary injury is also well established (55).  As mentioned above, the 
effects of chronic ethanol exposure on the liver and lung have most often been 
studied independently.  In order to study the possibility of interdependence 
between these two organs, a model of concomitant liver and lung injury must be 
established.  Once established, additional studies investigating possible links 
between liver and lung injury will allow a better understanding of inter-organ 
interactions in this model. 
 
B. Aims and proposals 
 
 
1. Protective effects of prebiotics in the setting of non-alcoholic liver 
disease 
 
Our lab has already shown that arsenic can sensitize the liver to non-alcoholic 
fatty liver disease caused by a high fat diet.   In this model, enhanced damage 
correlated with an increase in hepatic inflammation and in sinusoidal fibrin 
deposition in the liver.  Hepatic inflammation and injury caused by a HFD is 
mediated by multiple mechanisms, including gut dysbiosis.  Indeed, HFD feeding 
increases gut leakiness, causing endotoxemia and systemic inflammation (78) 
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and liver steatosis (79).  Protecting against endotoxemia by altering the 
microbiota caused by HFD exposure can also protect against inflammation and 
metabolic syndrome in mice (80).   Furthermore, the benefits of pre- and 
probiotics on liver injury have been established in models of alcoholic and non-
alcoholic liver disease (81-83).  Enhanced liver injury caused by the combination 
of HFD and arsenic in this model may be mediated by interactions between HFD 
and arsenic on the gut microbiome.  Therefore the goals of this study were to 1) 
determine the protective effects of oligofructose (OFC) and 2) to identify 
interactions between HFD, arsenic, and OFC on the gut microbiome in a model 
of enhanced liver injury caused by concomitant exposure to HFD and arsenic.  
Importantly, fibrin ECM deposition may play a key role in this response. 
 
2. Characterization of a model of concomitant liver and lung injury 
 
A number of studies independently investigating the liver and lung response 
to chronic alcohol exposure have indicated that similar mechanisms contribute to 
alcohol-induced changes in these two organs including oxidative stress, 
dysregulated inflammatory response, and tissue remodeling.  An important 
function of the liver is as a host-defense system; thus liver injury and the 
resultant reduction in hepatic function could enhance susceptibility of other 
organs to injury, including the lungs.  For example, mortality due to ARDS was 
increased to nearly 100% in individuals with end-stage liver disease (74).  This 
as well as work by Siore et al (84) have indirectly suggested that liver injury 
and/or hepatic-derived mediators may drive injury in the lung.  One potential link 
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between liver and lung injury is the pro-inflammatory cytokine TNFα.  TNFα 
levels in the systemic circulation are increased after alcohol exposure in both 
experimental models of alcohol exposure (85, 86) and in patients with ALD (77).  
The resident hepatic macrophages, Kupffer cells, are known to be a major 
source of pro-inflammatory mediators into the systemic blood (65, 87) and likely 
contribute to the robust increase in pro-inflammatory signaling after alcohol 
exposure.  Moreover, TNFα has also been linked to pulmonary injury in 
experimental models (88, 89).  Therefore, the purpose of this study was to 
characterize a model of concomitant liver and lung injury and to investigate the 
potential role of TNFα as link between liver and lung injury after chronic alcohol 
exposure.  These studies lay the groundwork for future studies on the interaction 
of the role of the liver in lung ECM remodeling in the ‘alcoholic lung phenotype.’ 
 
3. Can we characterize the hepatic extracellular proteome? 
 
As mentioned above, the role of the ECM in later stages of liver disease (i.e., 
fibrosis) is well recognized.  Previous studies from this lab and other groups (28, 
90) have shown that changes in the ECM also occur in early pre-fibrotic stages of 
liver disease.  These transitional changes in the ECM appear to play a critical 
role in the sensitization of the liver to insult, particularly in the context of fatty 
liver.  While several matrix proteins have been implicated as players in liver injury 
and inflammation (i.e., fibrin, fibronectin) there are likely other ECM proteins that 
also contribute to hepatic injury.  Identification of new ECM proteins that are 
altered by ethanol exposure would provide new insights into mechanisms of 
hepatic tissue remodeling that contribute to progression of ALD.  There are likely 
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changes in the hepatic ECM that have not yet been identified due to the 
insolubility of matrix proteins making them difficult to extract and analyze.  
Additionally, the study of alterations to the hepatic ECM has primarily been 
hypothesis-driven which can hamper the discovery of new potential players.  The 
purpose of this study was to use a serial extraction technique which would allow 
extraction and enrichment of tightly cross-linked proteins coupled with LC-MS 
analysis.  When paired together, these methods will allow extraction of proteins 
with low expression levels and poor solubility and analysis of global changes in 
the hepatic ECM. 
 
Overall aim of this dissertation. 
The overall aim of this dissertation is to build on the unifying hypothesis that 
ECM dyshomeostasis contributes to hepatic pathology, as well as to pathology in 
other organs, such as the lung.  Indeed, as described above, the enhancement of 
liver injury caused by arsenic exposure in the context of HFD (Aim 1) is 
characterized by a robust increase in fibrin deposition; the intervention strategies 
that protect against this pathology will shed new insight into future studies.  The 
development of a new model to characterize the interaction between liver and 
lung in the alcoholic lung phenotype (Aim 2), coupled with the new ECM 
proteomic strategies (Aim 3), lay the foundation for testing the hypothesis that 
liver injury is critical in transitional ECM remodeling that occurs with alcohol 
exposure (i.e., the ‘alcoholic lung phenotype’).  Taken together, this work will 
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shed new mechanistic insight into the complex interplay between injury, matrix 









A. Animals and treatments 
Mice were housed in a pathogen-free barrier facility accredited by the 
Association for Assessment and Accreditation of Laboratory Animal Care, and 
procedures were approved by the University of Louisville’s Institutional Animal 
Care and Use Committee.  
At time of sacrifice, animals were anesthetized with ketamine/xylazine 
(100/15 mg/kg, i.p.).  Blood was collected from the vena cava just prior to 
sacrifice by exsanguination and citrated plasma was stored for further analysis.  
Prior to lavage of the lungs, 10 mL of PBS was perfused through the heart to 
flush the pulmonary vasculature of erythrocytes.  Bronchioalveolar lavage (BAL) 
was performed by flushing the lung two times with 400 μL sterile PBS.  Cells in 
the BAL fluid (BALF) were separated by centrifugation and removed from 
remaining BALF and fixed on slides for further analysis (91).  Portions of liver 
tissue and lung tissue were snap-frozen in liquid nitrogen for later analysis or 
fixed in 10% neutral buffered formalin for subsequent sectioning and mounting on 
microscope slides.  A portion of liver tissue was frozen-fixed in Tissue Tek OCT-
Compound (Satura Finetek, Torrance, CA).  Total RNA was immediately 
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extracted from fresh liver and lung tissue using RNA-stat (Tel-Test, Austin, TX) 
and chloroform: phenol separation (see RNA isolation Methods).   
1. Arsenic, high fat diet, and oligofructose feeding 
Four week old male C57Bl6/J mice were purchased from the Jackson 
Laboratory (Bar Harbor, ME).  Food and tap water were allowed ad libitum.  Mice 
were fed AIN-76 Purified diet (Harlan Laboratories) for one week to reduce 
potential confounding factors of arsenic present in standard laboratory chow (92).  
Mice were exposed to sodium arsenite (4.9 ppm in drinking water) or tap water 
for one week prior to initiating feeding with either commercially available 
experimental diets (Table 2.1; Harlan Laboratories, Madison WI) including a low 
fat diet (LFD; 13% fat in calories), a high fat diet (HFD; 42% fat in calories), or a 
HFD containing the prebiotic oligofructose (5% w/w OFC) for 10 weeks.  This 
exposure level of arsenic was determined by preliminary range-finding 
experiments to cause no overt liver damage in mice fed low-fat diet.  Food and 
water consumption were measured twice a week.  Body weight was measured 
once a week 
2. Chronic model of alcohol exposure 
Eight week old male C57BL6/J mice were purchased from the Jackson 
Laboratory (Bar Harbor, ME) and exposed to either ethanol-containing Lieber-
DeCarli diet (Dyets, Inc.) or iso-caloric control diet.  During the exposure period, 
animals were housed in pairs in shoebox cages in a room held at 75 ⁰F.  Diet 
was provided in vacuum tubes and replaced between 4 and 5 pm daily.  Both 
ethanol-fed animals and their pair-fed counterparts received control diet for the  
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Table 2.1.  Diet Composition 
 
 Low Fat Diet  High Fat Diet 
 % kCal Source  
(% by weight) 
 % kCal Source  
(% by weight) 
Protein 19.2 Casein  15.2 Casein 
Carbohydrate 67.9 Sucrose/Corn starch  42.7 
Sucrose/Corn 
starch 
Fat 13.0 Milkfat (3.7%)/ soybean oil (1.3%)  42.0 Milkfat (21.2%) 




first two days of liquid diet feeding to allow acclimation to the liquid diet feeders.  
After 2 days of acclimation, ethanol concentrations increased incrementally over 
the course of three weeks before reaching the highest ethanol concentration, 6% 
(vol/vol) for the final three weeks of exposure.  Ethanol concentrations in the 
ethanol-containing diets were as follows: 0% for two days of acclimation, 1% for 
two days, 2% for two days, 4% for one week, 5% for one week, and 6% for three 
weeks.  Ethanol-containing diet was provided ad libitum for the entire course of 
the study.  Because of the relatively high caloric content of ethanol, pair-fed 
control animals received an iso-caloric control diet; the calories in the iso-caloric 
diet were matched by adding a calorie-equivalent of maltose-dextrin.  To account 
for the reduced food consumption of ethanol-fed mice, pair-fed mice were given 
the volume of diet consumed by their ethanol-fed counterparts the night before.  
At the conclusion of the feeding period, the two diet groups were further 
separated into additional groups that received either LPS (E. coli; 10 mg/kg i.p 
Sigma, St. Louis, MO) or vehicle (saline). Animals were euthanized 4 or 24 h 
after LPS (or vehicle) injection.  
a. Etanercept administration 
Etanercept (Etan; Wyeth) is an FDA-approved TNFα blocker.  Etanercept 
is a fusion protein of the human p75 TNF receptor attached to the Fc portion of 
human IgG1.  In this study, some animals were administered etanercept (10 
mg/kg in PBS) by i.p. injection two times per week during ethanol administration, 
as described by others (93, 94).  Control animals received PBS vehicle, (1 μl/g; 




1. 3-step ECM extraction (95-97) 
Sample preparation and wash. Snap frozen liver tissue  (75-100 mg) was 
immediately added to ice-cold phosphate-buffered saline (pH 7.4) wash buffer 
containing commercially available protease and phosphatase inhibitors (Sigma 
Aldrich) and 25 mM EDTA to inhibit proteinase and metalloproteinase activity, 
respectively.  While immersed in wash buffer, liver tissue was diced into small 
fragments using a scalpel.  The diced sample was washed 5 times to remove 
contaminants.  Between washes, samples were pelleted by centrifugation at 
10,000×g for 5 min and wash buffer was decanted.  NaCl extraction.  Diced 
samples were incubated in 10 volumes of 0.5 M NaCl buffer, containing 10 mM 
Tris HCl (pH 7.5), proteinase/phosphatase inhibitors, and 25 mM EDTA.  The 
samples were mildly mixed on a plate shaker (800 rpm) overnight at room 
temperature.  The following day, the remaining tissue pieces were pelleted by 
centrifugation at 10,000×g for 10 min.  The supernatant was saved and labeled 
as the NaCl fraction. SDS extraction.  The pellet from the NaCl extraction was 
subsequently incubated in 10 volumes (based on original weight) of a 1% SDS 
solution, containing proteinase/phosphatase inhibitors and 25 mM EDTA.  The 
samples were mildly mixed on a plate shaker (800 rpm) overnight at room 
temperature. The following day, the remaining tissue pieces were pelleted by 
centrifugation at 10,000×g for 10 min.  The supernatant was saved and labeled 
as the SDS extract.  Guanidine HCl extraction. The pellet from the SDS 
extraction was incubated with 5 volumes (based on original weight) of a 
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denaturing guanidine buffer containing 4 M guanidine HCl (pH 5.8), 50 mM 
sodium acetate, 25 mM EDTA, and proteinase/phosphatase inhibitors.  The 
samples were vigorously mixed on a plate shaker at 1200 rpm for 48 hours at 
room temperature; vigorous shaking is necessary at this step to aid in the 
mechanical disruption of ECM components.  The remaining insoluble 
components were pelleted by centrifugation at 10,000×g for 10 minutes.  This 
insoluble pellet was retained and solubilized as described below.  The 
supernatant was saved and labeled as the GnHCl fraction. Deglycosylation and 
solubilization.  The supernatants from each extraction were desalted using 
ZebaSpin columns (Pierce) according to manufacturer’s instructions.  The 
desalted extracts were then mixed with 5 volumes of 100% acetone and stored at 
-20⁰C overnight to precipitate proteins.  The precipitated proteins were pelleted 
by centrifugation at 16,000×g for 45 minutes.  Acetone was evaporated by 
vacuum drying in a RotoVap for 1 hour.  Dried protein pellets were resuspended 
in 500 uL deglycosylation buffer (150 mM NaCl, 50 mM sodium acetate, pH 6.8, 
10 mM EDTA, and proteinase/phosphatase inhibitors) that contained 
chondroitinase ABC (P. vulgaris; 0.025 U/sample), endo-beta-galactosidase (B. 
fragilis; 0.01 U/sample) and heparitinase II (F. heparinum; 0.025 U/sample).  
Samples were incubated overnight at 37⁰C.  Samples containing the pellet 
remaining after the guanidine HCl step received 20 uL DMSO to aide in 
solubilization.  Protein concentrations were estimated by absorbance at 280 nm 




2. Sample cleanup and preparation for liquid chromatography 
Pooled samples in deglycosylation buffer were provided to and 
subsequently analyzed by the University of Louisville Proteomics Biomarkers 
Discovery Core (PBDC).  At the PBDC, samples in deglycosylation buffer were 
thawed to room temperature and clarified by centrifugation at 5,000xg at 4°C for 
5 min.  Samples were reduced by adding 5.55 µL of 1 M DTT to 50 µL (25 µg) of 
each sample and then incubating at 60°C for 30 min after which 144.45 µL of 8 M 
urea in 0.1 M Tris-HCl pH 8.5 was added to each sample.  Each reduced and 
diluted sample was digested with a modified Filter-Aided Sample Preparation 
(FASP) method.  Recovered material was dried in a SpeedVac and redissolved 
in 200 μL of 2% (v/v) acetonitrile (ACN)/0.4% formic acid (FA).  The samples 
were then trap-cleaned with a C18 PROTOTM 300Å Ultra MicroSpin Column (The 
Nest Group, Southborough, MA).  The sample eluates were stored at -80°C for 
30 min, dried in a SpeedVac, and stored at -80°C until analysis.  Before liquid 
chromatography, dried samples were warmed to room temperature and 
dissolved in 2% (v/v) ACN/0.1% FA to a final concentration of 0.25 μg/μL. For 
analysis 16 μL (4 μg) of sample was injected into the Orbitrap Elite. 
3. Liquid Chromatography 
Dionex Acclaim PepMap 100 75 μm x 2 cm nanoViper (C18, 3 µm, 100 Å) 
trap and Dionex Acclaim PepMap RSLC 50 μM x 15 cm nanoViper (C18, 2 µm, 
100 Å) separating columns were used.  An EASY n-LC (Thermo, Waltham, MA) 
UHPLC system was used with buffer A = 2% (v/v) acetonitrile / 0.1% (v/v) formic 
acid and buffer B = 80% (v/v) acetonitrile / 0.1% (v/v) formic acid as mobile 
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phases.  Following injection of the sample onto the trap, separation was 
accomplished with a 140 min linear gradient from 0% B to 50% B, followed by a 
30 min linear gradient from 50% B to 95% B, and lastly a 10 min wash with 95% 
B.  A 40 mm stainless steel emitter (Thermo, Waltham, MA; P/N ES542) was 
coupled to the outlet of the separating column.  A Nanospray Flex source 
(Thermo, Waltham, MA) was used to position the end of the emitter near the ion 
transfer capillary of the mass spectrometer.  The ion transfer capillary 
temperature of the mass spectrometer was set at 225°C, and the spray voltage 
was set at 1.6 kV. 
4. Mass Spectroscopy 
An Orbitrap Elite – ETD mass spectrometer (Thermo) was used to collect 
data from the LC eluate.  An Nth Order Double Play with ETD Decision Tree 
method was created in Xcalibur v2.2.  Scan event one of the method obtained an 
FTMS MS1 scan for the range 300-2000 m/z.  Scan event two obtained ITMS 
MS2 scans on up to ten peaks that had a minimum signal threshold of 10,000 
counts from scan event one.  A decision tree was used to determine whether 
collision induced dissociation (CID) or electron transfer dissociation (ETD) 
activation was used.  An ETD scan was triggered if any of the following held:  an 
ion had charge state 3 and m/z less than 650, an ion had charge state 4 and m/z 
less than 900, an ion had charge state 5 and m/z less than 950, or an ion had 
charge state greater than 5; a CID scan was triggered in all other cases.  The 
lock mass option was enabled (0% lock mass abundance) using the 371.101236 
m/z polysiloxane peak as an internal calibrant.   
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5. Data Analysis  
Proteome Discoverer v1.4.0.288 was used to analyze the data collected by 
the mass spectrometer.  The database used in Mascot v2.4 and SequestHT 
searches was the 6/2/2014 version of the UniprotKB Mus musculus reference 
proteome canonical and isoform sequences.  In order to estimate the false 
discovery rate, a Target Decoy PSM Validator node was included in the 
Proteome Discoverer workflow.   
The Proteome Discoverer analysis workflow allows for extraction of MS2 
scan data from the Xcalibur RAW file, separate searches of CID and ETD MS2 
scans in Mascot and Sequest, and collection of the results into a single file (.msf 
extension). The resulting .msf files from Proteome Discoverer were loaded into 
Scaffold Q+S v4.3.2.  Scaffold was used to calculate the false discovery rate 
using the Peptide and Protein Prophet algorithms.  The results were annotated 
with mouse gene ontology information from the Gene Ontology Annotations 
Database 
C. Clinical chemistry 
Levels of alanine aminotransferase (ALT) and aspartate aminotransferase 
(AST) were determined spectrophotometrically using standard kits (Thermotrace, 
Melbourne, Australia). 
D. Hepatic lipid measurements 
Total lipid was extracted from mouse livers as previously described (98, 99).  
Briefly, mouse liver (25-50 mg) was pulverized in a liquid-nitrogen cooled mortar 
and pestle. Pulverized liver tissue was incubated in a methanol:chloroform (2:1) 
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mixture on ice for thirty minutes.  At the end of incubation, extracts were 
centrifuged at 900 x g for 10 min at 15⁰C.  After centrifugation, lipids are 
partitioned into the chloroform (bottom) layer. This bottom layer was removed 
using a glass syringe and dried in an evaporating centrifuge.  The resulting pellet 
was resuspended 5% fatty acid-free bovine serum albumin then frozen at -80⁰C 
overnight.  Prior to analysis, samples were vortexed then sonicated for 10 
minutes at 37⁰C in a bath sonicator.  Hepatic triglyceride (Thermo Scientific, 
Middletown, VA) non-esterified fatty acids (Sigma Aldrich, St. Louis MO) were 
determined using standard kits.  Values were normalized to initial liver tissue 
weight.   
E. Histology 
1. General morphology 
Formalin fixed, paraffin embedded liver and lung tissue were cut at 5 μm and 
mounted on charged glass slides.  Sections were deparaffinized with Citrisolv 
(Fisher, Waltham, MA) and rehydrated through graded ethanol.  Sections were 
then stained with hematoxylin and eosin (H&E).  After staining, samples were 
dehydrated through graded alcohol, washed in Citrisolv and then mounted with 
Permount (Fisher, Waltham, MA).   
2. Neutrophil accumulation 
Chloroacetate esterase (CAE) staining for neutrophils was performed using 
the naphthol AS-D chloroacetate esterase kit (Sigma, St. Louis, MO) on paraffin 
embedded sections (5 μm). For blinded quantitation, samples were de-identified 
and 10 fields were photographed at 400x magnification and saved.  For liver 
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tissue, the extent of CAE staining was quantified by counting the number of CAE-
positive neutrophils per 1000 hepatocytes (69).  For lung tissue, total CAE-
positive cells were counted per 10 fields.  During quantification, neutrophils were 
characterized by light pink (i.e. CAE-positive) staining and bi-lobed nuclear 
morphology. 
3. Immunohistochemistry 
Immunohistochemical staining for the marker F4/80 was performed as 
previously described (98).  Formalin-fixed, paraffin embedded sections (5 μm) 
were deparaffinized and rehydrated with graded ethanol solutions.  Endogenous 
peroxidase activity was quenched by incubating slides in a 3% H2O2 solution for 
5 minutes at room temperature.  Because the liver has high concentrations of 
biotin, an avidin-biotin blocking reagent (Dako, Carpinteria, CA) was used to 
reduce non-specific staining.  Slides were then incubated in primary antibody for 
the F4/80 cell surface receptor (1:500 in 10% goat serum; Abcam, Cambridge 
MA) for two hours at room temperature.  The Vectastain Elite ABC kit was used 
for detection (Vector Laboratories, Inc., Burlingame, CA).  Briefly, tissue was 
incubated in a biotinylated anti-Rat IgG secondary antibody for 15 minutes at 
room temperature.  Tissue was then washed and incubated in a solution 
containing avidin-bound horseradish peroxidase (HRP) for 30 minutes.  The HRP 
substrate 3, 3’-diaminobenzidine (DAB) was added to tissue sections until 
positive (brown) staining was macroscopically visible.  Slides were 
counterstained with Hematoxylin (Dako, Carpinteria, CA) for 1 minute, washed, 
dehydrated through graded ethanol and then mounted with Permount (Fisher, 
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Waltham, MA).  Each slide contained a negative tissue section which does not 
receive primary antibody.  The number of F4/80 macrophages in liver tissue was 
quantified by blinded counting of the number of F4/80 positive macrophages per 
1000 hepatocytes in 200x photomicrographs. 
4. Immunofluorescence 
Immunofluorescent detection of fibrin deposition was performed as described 
in (69).  Briefly, frozen liver sections (6 μm thick) were fixed in 10% buffered 
formalin containing 2% acetic acid to solubilize all but cross-linked fibrin.  
Sections were blocked with PBS containing 10% horse serum before an 
overnight incubation at 4⁰C with affinity purified rabbit anti-human fibrinogen IgG 
(Dako North America, Inc. Carpinteria, CA) diluted in blocking solution.  Donkey 
anti-rabbit antibody conjugated to Alexa 488 (Invitrogen, Carlsbad, CA) was used 
as secondary antibody.  Tissue was counterstained with Hoechst.  Fluorescence 
for Alexa 488 and Hoechst was detected at excitation and emission wavelengths 
of 490 nm and 520 nm, and 350 nm and 460 nm, respectively.  
Immunofluorescence was visualized using a Nikon Eclipse E600 microscope 
(Nikon Corporation, Tokyo, Japan) and Metamorph software 
F. RNA isolation and real-time RT-PCR 
The hepatic mRNA expression of select genes was detected by quantitative 
reverse-transcriptase polymerase chain reaction (RT-PCR), which is routine for 
this group (29, 50, 98, 100).   PCR primers and probes for TNFα, PAI-1, IL-6, and 
β-actin were designed using Primer 3 (Whitehead Institute for Biomedical 
Research, Cambridge, MA).  Primers and probes for KC, MIP-2, and IL-10 were 
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bought from Applied Biosystems as kits (Foster City, CA).  All primers were 
designed to cross introns to ensure that only cDNA and not genomic DNA was 
amplified.    Total RNA was extracted from liver tissue by a guanidinium 
thiocyanate-based method (RNA STAT 60 Tel-Test, Ambion, Austin, TX).  RNA 
concentrations were determined spectrophotometrically and 1 μg of total RNA 
was reverse transcribed using a kit (Quanta Biosciences, Gaithersburg, MD).  
PerfeCta qPCR Fast Mix (Quanta Biosciences, Gaithersburg, MD) was used to 
prepare the PCR reaction mixture.   This 2× mixture is optimized for TaqMan 
reactions and contains MgCl2, dNTPs, and AccuFast Taq DNA Polymerase.   
Amplification reactions were carried out using the ABI StepOne Plus machine 
and software (Life Technologies, Grand Island, NY) with initial holding stage 
(95⁰C for 30 seconds) and 50 cycles of a 2-step PCR (95⁰C for 30 seconds, 
60⁰C for 20 seconds).    Fluorescent intensity of each sample was measured at 
each cycle to monitor amplification of the target gene.  The comparative CT 
method was used to determine fold changes in mRNA expression compared to 
an endogenous reference gene (β-actin).  This method determines the amount of 
target gene, normalized to an endogenous reference and relative to a calibrator 
(2-ΔΔCt).   
G. Luminex   
Cytokine levels in plasma and BALF samples were measured using the 
MILLIPLEX MAP Magnetic Bead Mouse Cytokine/Chemokine Panel (Millipore, 
Billerica, MA). The plate was read using a Luminex 100 plate reader and 
Exponent software.  MILLIPLEX MAP assay was performed according to 
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manufacturer’s recommendations.  Plasma (4x dilution) or BALF samples 
(undiluted) were added to a clear bottomed black 96 well plate. Antibody-
immobilized beads were added to samples and the plate was incubated 
overnight at 4⁰C on a plate shaker at 600 rpm.  Detection antibody was added to 
wells and incubated for 1 hour followed by the addition of strepavidin-
phycoerythrin.   Quantitative analysis of the assay was performed using the 
Luminex 100TM IS.  Data capture and analysis were performed using the Luminex 
Xponent software. 
H. Microbiota analysis 
1. Bacterial DNA isolation and sequencing 
DNA was extracted from frozen cecal pellet and plasma using the QIAamp 
DNA Stool Mini Kit (Qiagen) according to the manufacturer’s directions.   
Briefly, cecal content (75-100 mg) was rapidly weighed, recorded, and placed 
into a 2 mL microcentrifuge tube on ice.  Lysis buffer was added to each 
sample and the sample was vortexed until thoroughly homogenized. 
Homogenized sample was heated at 70⁰C for 5 minutes and then vortexed at 
full speed for 1 minute to pellet particles.  Supernatant was removed and 
added to a new tube with an InhibitEX tablet (supplied by kit) which forms a 
matrix to pellet DNA-degrading enzymes.  Samples were centrifuged to pellet 
inhibitors bound to the matrix; remaining supernatant was added to a new 
tube and incubated with proteinase K.  DNA was then precipitated with 




100 ng of cecal DNA was sent to Baylor University School of Medicine’s 
Alkek Center for Metagenomics and Microbiome Research for 16S rRNA 
sequencing on the 454 FLX-titanium Platform.  The V3–V5 16S rRNA gene 
variable regions were amplified by PCR using 454 adapter-linked and bar-
coded primers 357F and 926R, as described previously (101). Negative 
controls (water) and positive controls (Staphylococcus aureus USA300 
genomic DNA) were included in all steps to control for contamination. 
Amplicons were purified using a SPRI bead clean-up step, quantitated by 
picogreen assay, normalized, pooled, and then sequenced on a 454 
instrument using the FLX Titanium chemistry. 
2. Bacterial DNA analysis 
The raw sequencing dataset, consisting of an average of 28,590 reads per 
sample with an average read length of 253 nucleotides, was deconvoluted 
via the PyNAST alignment tool (102) using the Greengenes reference 
database (August 2013 release) (103) and quality filtered with cutoff 
parameters of:  less than 200 and greater than 1,000 bp, quality score below 
30, number of mismatches in primer greater than 0, number of ambiguous 
bases greater than 6, and maximum homopolymer runs greater than 6.  
Following quality filtering, 514,622 sequences remained from the original 
531,138 with an average read length of 253 nucleotides.  Chimeric 
sequences were removed by reference and de novo chimeric filtering with 
UCHIME (104) utilizing the Greengenes reference database (August 2013 
release) (103).  Operational taxonomic unit tables based on sequences 
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within the filtered data set were then generated by taxonomic binning via the 
Quantitative Insights Into Microbial Ecology tool (Qiime) and its various 
components (104). Open reference OTU picking was performed via Usearch 
6.1 software (105) using 97% similarity to the clustered Greengenes 
database from August 2013 (106) while removing singleton OTUs from the 
OTU table as further quality filtering to improve specificity.  The taxonomic 
classifications of sequence reads were identified from the phylum to the 
species level by the uclust based consensus taxonomy classifier (Bokulich, 
Rideout et al. (submitted))  with phylogenetic tree creation by Fast Tree 
(107).  For diversity measures, an even sequence sampling depth of 16,000 
sequences was used to avoid artifacts due to differing numbers of 
sequences per sample.  PCoA analyses were performed to compare 
microbial community structure between samples utilizing weighted UniFrac 
measures (108).  Linear effect size (LefSe) analyses were performed using 
the freely distributed Galaxy LefSe analysis module hosted at 
huttenhower.sph.harvard.edu/lefse/ (109).  Hypothesis testing using the 
Dirichlet-Multinomial Distribution was performed via the HMP package for R 
(110) within the R Statistical Computing Environment (111) 
I. Statistical Analysis 
Results are reported as means ± standard error mean (SEM; n = 4-7).  
ANOVA with Bonferroni’s post-hoc test (for parametric data) or Mann-Whitney 
Rank Sum test (for nonparametric data) was used for the determination of 
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statistical significance among treatment groups, as appropriate.  A p value less 





OLIGOFRUCTOSE PROTECTS AGAINST ENHANCED LIVER INJURY 
CAUSED BY ARSENIC IN A MODEL OF HIGH FAT DIET INDUCED NON-




Exposure to high concentrations of arsenic (As) is associated with a myriad of 
health effects including skin lesions, hypertension, cardiovascular disease, 
respiratory disease, and malignancies of the skin and internal organs (112).  The 
liver, a major site of arsenic metabolism, is a known target of arsenic toxicity 
(113).  Indeed, chronic arsenic exposure causes hepatomegaly, non-cirrhotic 
portal fibrosis and portal hypertension (113-115).  The concentrations of arsenic 
found in the US water supply are generally considered lower than those 
necessary to cause overt liver damage, however lower levels of arsenic can 
cause more subtle changes in the liver (46) and can sensitize the liver to injury 
by another insult (47). Therefore, while arsenic levels in the US may not be high 
enough to directly injure the liver, there is evidence that low levels of arsenic may 
interact with other risk-modifying factors to cause hepatic injury. 
Obesity is another major health concern for the US and globally.  More than 
one third of American adults are obese (116), and it is expected that the number 
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of obese individuals in the US will double by 2050 (117).  Obesity is associated 
with a myriad of health effects including insulin resistance, diabetes, and non-
alcoholic fatty liver disease (NAFLD).  NAFLD is a spectrum of disease states 
including simple steatosis, non-alcoholic steatohepatitis, and fibrosis and 
cirrhosis.  Studies have shown that about 20-30% the general population has 
NAFLD (118) however studies have shown that the prevalence of NAFLD can 
more than double in obese cohorts (119).  Despite the high incidence of NALFD 
in obese populations, only a minority of obese individuals ever progress to more 
severe stages of liver disease, such as non-alcoholic steatohepatitis.  Risk 
factors for primary NAFLD include obesity, type II diabetes and dyslipidemia 
(120).  However it is likely that other unidentified risk factors contribute to 
progression to more severe stages of liver disease (i.e. NASH).   
Interestingly, there is potential overlap in areas of risk for arsenic exposure 
and obesity.  For example, rural communities, which have both artesian water 
supplies that are unregulated by Clean Water Act, often have high arsenic 
concentrations; these areas also generally have a high prevalence of obesity.  In 
a study investigating the possible interaction between obesity and arsenic, this 
group demonstrated that low levels of arsenic synergistically enhance liver 
damage caused by high fat diet (98).  These data suggest that underlying risk 
factors, such as obesity, may modify the risk of hepatic injury caused by 
subhepatotoxic levels of arsenic exposure. However, the mechanism(s) 
underlying enhanced liver injury remain unknown. 
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The role of the gut:liver axis in liver disease is well recognized.  Indeed, liver 
injury is associated with dysbiosis, disruption of gut barrier integrity, and leakage 
of inflammatory bacterial-derived components (i.e., endotoxin) from the gut into 
the systemic circulation.  Obesity can affect gut permeability by decreasing the 
barrier function of the epithelium (78).  Additionally, both obesity and arsenic 
have been shown to alter gut flora (121).  Interestingly, probiotics, live bacteria 
cultures which promote commensal bacteria growth, can preserve intestinal 
barrier integrity and protect against liver injury in animals (81, 122).  Clinical 
studies have shown that probiotic supplementation improves patient outcome 
compared to standard therapy (123) via gut-mediated mechanisms.  Prebiotics, 
dietary compounds that favor the growth and maintenance of commensal 
bacteria, may also confer protective effects in the setting of liver injury via gut-
mediated mechanisms.  For example, Cani et al showed that the prebiotic 
oligofructose (OFC) can protect against inflammation and endotoxemia by 
regulating the microbiota of animals fed high fat diet (78).  Recently, arsenic 
exposure has been shown to also cause dysbiosis in mice (124), which could, in 
principle, exacerbate the effect of HFD.  The purpose of the current study was to 
test this hypothesis and to determine if the prebiotic oligofructose can protect 







B. EXPERIMENTAL PROCEDURES 
1. Animals and treatments 
Animals were exposed to combinations of HFD, arsenic and the prebiotic 
oligofructose as described in Chapter II. 
2. Clinical Chemistry 
Plasma levels of ALT and AST were determined as described in Chapter II 
3. Lipid determination 
Lipids were extracted from snap-frozen liver as described in Chapter II.  
Triglycerides and non-esterified fatty acids were determined as described in 
Chapter II.   
4. Immunostaining 
Hematoxylin and eosin staining, immunohistochemical staining for F4/80 and 
immunofluorescent staining for fibrin were performed on liver tissue as described 
in Chapter II. 
5. RNA isolation and real-time PCR 
Details for RNA isolation and real time PCR are described in Chapter II. 
6. Cecal DNA extraction 
DNA was extracted from cecal content as described in Chapter II. 
7. Microbiome analysis 
Metagenomic analysis of the cecal microbiome was performed as described 
in Chapter II. 
8. Statistical analysis 





1. Body and organ weight 
All animals gained weight and there was no mortality or morbidity in any 
group during the course of the study.  As observed previously (98), arsenic did 
not significantly affect food consumption or body mass gain in animals fed either 
LFD or HFD (Figure 3.1A and B).  High fat diet significantly increased food 
consumption ~20% and body mass gain ~50% compared to low fat diet alone 
(Figure 3.1C).  Whereas OFC supplementation did not affect food consumption, it 
did significantly attenuate the increase body mass gain caused by HFD; this 
effect of OFC was independent of the presence of arsenic in the diet.   
 
2. OFC protects against liver Injury 
HFD significantly increased the percent liver to body weight compared to low 
fat diet (Figure 3.2B).  Liver weight to body weight percent was not significantly 
affected by concomitant arsenic exposure or by oligofructose feeding.  As 
expected by the hepatomegaly observed, 10 weeks of HFD feeding dramatically 
increased lipid accumulation in the liver (Figure 3.2A); this pathologic change 
comprised both macrovesicular and microvesicular steatosis.  Changes in 
quantity of hepatic triglycerides and non-esterifieid fatty acids (NEFA) (Figure 
3.2B) were also determined.  HFD alone increased hepatic triglyceride and NEFA 
content compared to LFD alone by more than 4 fold.  Arsenic administration did  
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Figure 3.1:  Model parameters 
 
(A) Animals were exposed to arsenic (or tap) water for 11 weeks. One week after 
the start of arsenic exposure experimental diet (e.g. LFD, HFD, or HFD +OFC) 
was provided as described in Chapter II. (B) Body weight and food consumption 
were recorded once per week for the duration of the experiment.   Data are 
shown as +/- SEM (n = 6-10). a, p < 0.05 compared to tap water control; b, p < 







Figure 3.2: OFC protects against liver injury and steatosis.   
 
(A) Representative photomicrographs depicting hematoxylin & eosin staining 
(H&E, 200x; top left) are shown (B) Liver to body weight percent (LW/BW%) was 
determined as described in Materials and Methods.  Hepatic non-esterified fatty 
acid (NEFA) and triglyceride (TG) content (top right) were determined using kits 
as described in Materials and Methods. Plasma levels of alanine and aspartate 
aminotransferase were determined as an index of liver injury.  Quantitative data 
are shown as +/- SEM (n =6-10).  a, p < 0.05 compared to tap water control; b, p 









































































































































































































































not affect steatosis or hepatic triglyceride or NEFA content when, in either LFD- 
or HFD-fed animals.  Oligofructose administration blunted fat accumulation and 
significantly decreased triglyceride content compared to animals that received 
either HFD or arsenic + HFD without OFC.  Interestingly, OFC had no significant 
effect on NEFA content of the liver. 
HFD feeding also increased the appearance of necroinflammatory foci in the 
liver (Figure 3.2A).  Circulating levels of the liver enzymes alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST) were determined 
as indices of liver damage (Figure 3.2B).  HFD alone significantly increased ALT 
levels, but did not significantly affect AST levels.  Whereas arsenic did not 
significantly affect plasma levels of either ALT or AST in the LFD group, it 
significantly enhanced the increase in these variables caused by HFD under 
these conditions by ~50%.  The addition of OFC to animals receiving HFD did not 
affect the transaminase levels in the absence of arsenic.  However, OFC 
administration completely blunted the increase in both ALT and AST caused by 
the combined exposure of arsenic and HFD.   
 
3. OFC protects against inflammation 
Immunohistochemistry for F4/80, a marker of activated macrophages, was 
performed as an index of inflammation (Figure 3.3A).  Neither arsenic nor HFD 
alone altered the number of F4/80 positive macrophages; however the 
combination of arsenic + HFD significantly increased the number of hepatic 
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Figure 3.3: OFC protects against hepatic inflammation.  
 
(A) Representative photomicrographs of immunohistochemical staining for F4/80 
(200x) are shown.  (B) Number of F4/80 positive cells were counted per 1000 
hepatoctyes as described in Chapter II.  C. Real time RT-PCR was performed for 
the pro-inflammatory geneTNFα as described in Chapter II. Data are shown as 
+/- SEM (n = 6-10). a, p < 0.05 compared to tap water control; b, p < 0.05 












































































































macrophages compared to arsenic or HFD alone, as was observed previously 
(98).  The administration of OFC significantly blunted the increase in number of 
activated macrophages caused by the combination of arsenic and HFD and 
values were similar to those of LFD controls.   
 
4. OFC protects against fibrin deposition 
Previously, the enhancement of HFD-induced liver injury caused by arsenic 
correlated with a significant increase in hepatic expression of PAI-1 (98).  PAI-1 
is a major inhibitor of both tissue-type plasminogen activator (tPA) and 
urokinase-type plasminogen activator (uPA), and is therefore a key inhibitor of 
fibrin degradation (i.e., fibrinolysis) by plasmin.  Fibrin deposition was determined 
by immunofluorescent staining and quantitation of fluorescent signal. LFD-fed 
animals given either tap or arsenic-containing water had minimal fibrin deposition 
in the liver (Figure 3.4A).  HFD alone increased deposition of fibrin by ~2-fold.  As 
observed previously (98), the combination of HFD + arsenic significantly 
increased the expression of PAI-1 and fibrin deposition in liver (Figure 3.4B).  
OFC administration almost completely prevented the changes caused by arsenic 
under these conditions.   
 
5. Effects on the microbiome  
The effects of arsenic, HFD, and OFC on relative abundance and total 
abundance of bacteria was determined at the phylum level (Figure 3.5A).  As 
expected, the most abundance bacteria phyla were Bacteroidetes and 
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Figure 3.4: OFC protects against sinusoidal fibrin accumulation.   
 
A. Representative photomicrographs (400x) of immunofluorescent staining for 
fibrin are shown.  B. Fibrin immunofluorescence (green color) was quantitated 
using Metamorph software.  C.  Hepatic PAI-1 mRNA expression was 
determined using real time RT-PCR.  Data are shown as +/- SEM (n = 6-10). a, p 
< 0.05 compared to tap water control; b, p < 0.05 compared to LFD; c, p < 0.05 









































































































Firmicutes.  Arsenic exposure alone caused a loss of the Verrucobiorobia in 
animals that were fed a LFD.  Interestingly, this effect was lost in animals that 
were fed a HFD; however, the combination of arsenic and HFD did lead to an 
increase in the gram-negative phyla Bacteroidetes.  Oligofructose feeding 
increased the relative abundance of Bacteroidetes with a concomitant decrease 
in Firmicutes compared to all other groups that did not receive the prebiotic.  
Additionally, OFC restored the growth of Tenericutes which was lost in animals 
that received a HFD.  OFC also resulted in a robust increase in total bacteria 
compared to animals that did not receive OFC.   
α diversity (Figure 3.5B) was used as a measure of diversity within a sample.  
Interestingly, the greatest α diversity was observed in animals exposed to a LFD.  
HFD feeding reduced α diversity and the combination of HFD and OFC resulted 
in the lowest α diversity of all six groups.  β diversity was used as a measure of 
diversity between samples (Figure 3.5C).  As expected, samples that represent a 
single treatment group clustered more closely together, suggested a higher 
degree of similarity among the samples.   
Linear discriminant analysis effect size (LefSe) was used to identify the 
enrichment of bacteria within treatment groups.  When all six treatment groups 
were compared, unique enrichment profiles were observed for each group 
(Figure 3.6A).  In a LefSe comparison between the LFD and LFD + arsenic, 
enrichment was primarily seen in animals that received tap water, suggesting 
that arsenic exposure resulted in decreases in these bacteria including the 
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Figure 3.5: Effects of HFD, arsenic, and OFC on bacterial abundance and 
diversity.  
 
A. The top stacked bar chart shows the relative abundance of bacteria phyla for 
each group.   Absolute abundance (bottom) was determined by averaging the 
total number of OTUs found in each bacterial phyla per group.  B. Alpha diversity, 
a measure of unique OTUs present in a given sample, is shown as an index of 
diversity within a sample.  Alpha rarefaction curves were determined by counting 
the number of sequences found in a sampling of bacterial DNA.  During the first 
sampling, all sequences identified were counted towards the number of observed 
OTUs; for each additional sampling, only unique OTUs are counted and added to 
the number of observed OTUs for that sample.  This process is repeated until a 
total of 16,000 sequences are sampled.  C. Beta diversity is shown as a measure 
of diversity between samples. This measure was determined using principle 
coordinate analysis of the phylogenetic diversity between samples and the 
differences in OTU abundance between samples.  Samples that are closer in 
proximity have microbiomes that are more similar in term of phylogenetic 














































































































































































































Figure 3.6:  HFD, arsenic, and OFC exposure caused unique changes to the 
microbiome.   
 
LefSe analysis was used to determined enrichment of taxa between groups. 
Effect size is determined using linear discriminant analysis (LDA).  A. LefSe 
analysis of all six treatment groups is plotted on a cladogram.  Each treatment 
group is represented by a unique color; highlighted taxa indicate enrichment of 
that taxa within the treatment group.  Effect size is represented by the size of the 
circular intersection points between the taxa.  B. Bar plot of LefSe analysis 
comparing the gut microbiomes of animals fed either LFD or a LFD and arsenic 
(top).  Each bar represents a bacterial taxa that was enriched by LFD.  The 
length of the bar represents the effect size.  C. Bar plot of LefSe analysis 
comparing the gut microbiomes of animals fed either HFD (blue), HFD and 
arsenic (red), or HFD, arsenic, and OFC (green).  The length of the bar 












commensal Bifidobacterium (Figure 3.6B).  Comparisons between animals fed 
HFD with or without arsenic and OFC showed that arsenic exposure was 
associated with a decrease in Mogibacteriacaceae and Turicibacter (Figure 
3.6C).     
 
D. DISCUSSION 
The GI tract is home to approximately 100 trillion gut microbes (125).  The 
microbes residing in the gut regulate many important physiological functions 
including metabolic processing, energy production, and immune system 
development (125).  Therefore, it is not surprising that dysbiosis of the gut flora is 
associated with a myriad of disease states locally in the GI tract including 
diarrhea/malabsorption (126, 127) and irritable bowel disease (128, 129).  
Because of the critical importance of the microbiome in immune surveillance and 
tolerance, changes in the gut microbiome are also linked to autoimmune and 
diseases (130-132).  The gut microbiome does not only contribute to diseases of 
the GI tract.  Indeed, several studies indicated that distal organ systems, 
including the CNS, are negatively affected by gut dysbiosis (133).   
A major mechanism by which gut dysbiosis may contribute to systemic 
disease is via changing/impairing the GI tract barrier function.  For example, 
rodent models of obesity have been associated with altered gut microbiota that 
favor gut leakiness (78, 79) and endotoxemia (78, 80).  Furthermore, dysbiosis 
associated with obesity contributes to the development of inflammation (78, 80) 
metabolic syndrome (134, 135), and non-alcoholic fatty liver injury (79).  The 
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understanding that the GI tract contributes to liver injury (i.e., the gut-liver axis) 
has been understood for over a century and was first shown experimentally more 
than 60 years ago by Rutenberg et al, when they demonstrated that 
nonabsorbable antibiotics protected against diet-induced liver injury (136).  Since 
then, many studies using a myriad of models including antibiotics (137, 138), and 
germ-free mouse models (139) have provided additional evidence implicating the 
microbiome in the susceptibility and development of liver disease.  Today, the 
gut-liver axis and enteric dysbiosis, including that caused by a HFD, is a 
generally accepted component in the development of liver disease. 
Although the role of arsenic in altering the microbiome is less well studied, 
arsenic is known to alter the microbial components of soil (140).  A recent study 
by Lu et al has shown that high levels of arsenic can cause dysbiosis in mice 
(124).  In their study, metagenomic analysis of the gut flora of mice exposed to 
50 ppm arsenic showed that arsenic significantly altered the abundance of some 
microbial families and also resulted in functional changes in the microbiome’s 
metabolic profile (124).  The changes in the gut flora caused by arsenic in the 
current study were more subtle than those seen by Lu and colleagues; this 
difference may be attributed, in part, to the >10-fold lower arsenic concentrations 
used in the current study.  Nevertheless, arsenic exposure did change the mouse 
microbiome in the current study; importantly, arsenic further exacerbated the 
dysbiosis caused by HFD feeding in mice.  Importantly, supplementation with 
oligofructose, a prebiotic that has been demonstrated to protect against dysbiosis 
and favor commensal bacteria, almost completely prevented the enhancement of 
56 
 
HFD-induced liver injury caused by arsenic.  These results therefore support the 
hypothesis that arsenic mediates liver injury under these conditions via 
mechanisms that involve the gut-liver axis. 
There are several potential mechanisms by which the microbiome may 
mediate arsenic-induced liver injury.  First, the changes in the microbiome 
caused by diet (HFD and OFC) may affect arsenic metabolism and absorption.  
Indeed, interactions between gut microbes and arsenic are bidirectional.  For 
instance, Pinyayev et al showed that bacteria from the mouse cecum can 
metabolize arsenic (141) and others have shown that the human gut flora can 
metabolize arsenic into toxic metabolites (142, 143).  Whereas this is distinctly 
possible, it should be noted that concentrations that are 10-fold higher than used 
here were not directly hepatotoxic (47).  Alternatively, the effects of arsenic on 
the microbiome may mediate the observed hepatotoxicity.  Indeed, arsenic 
exposure expanded the population of Gram negative bacteria that could produce 
endotoxins, which are well known for contributing to fatty liver injury.  However, 
whether the effects are driven by microbiome changes on arsenic levels, or by 
arsenic changes on the microbiome, these changes may potentiate arsenic 
toxicity locally on the gut epithelium (144) and contribute to enhanced arsenic 
toxicity distally in the liver.   
In addition to direct effects on the microbiome, the protective effect of OFC 
feeding under these conditions could also be ‘upstream’ of arsenic.  Specifically, 
OFC feeding significantly attenuated the increase in hepatic lipids caused by 
HFD, both in the presence and absence of arsenic.  The multi-hit hypothesis of 
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fatty liver disease involves not only an increase in gut-derived products that 
damage the liver, but also an increased sensitivity to the damage caused by 
these gut-derived products.  Indeed, fatty livers are more sensitive to a second 
toxic ‘hit,’ including gut-derived LPS (145, 146).  Therefore, the favorable effects 
of OFC on hepatic steatosis may indirectly protect against the injury caused by 
HFD and/or arsenic by blunting this sensitization.  In support of this hypothesis, 
enhanced liver injury caused by arsenic + HFD co-exposure was not due to an 
increase in steatosis per se, but rather due to an enhanced hepatic inflammatory 
response.  Therefore, OFC may also be protecting against damage in this model 
by preventing hepatic sensitization caused by HFD-induced endotoxemia.  Such 
a mechanism is supported by previous studies that arsenic-exposed livers are 
more sensitive to exogenous LPS (47) and that liver injury here in OFC-fed mice 
was insensitive to arsenic administration. 
In conclusion, protection against enhanced liver injury conferred by OFC is 
likely due to both direct effects on the microbiome, as well indirect effects on 
hepatic sensitization.  These findings are in-line with previous work, in which 
OFC supplementation was shown to protect against direct effects of HFD on the 
gut microbiome and barrier function (80).  Prebiotics favor an environment in 
which commensal bacteria can thrive, in lieu of direct delivery of commensal 
bacteria (i.e., probiotics).  As such, this approach may yield more predictable and 
stable results.  Nevertheless, these results serve proof-of-principle that protecting 
against microbiome changes caused by arsenic can prevent the enhancement of 





CHARACTERIZATION OF THE LINK BETWEEN LIVER AND LUNG INJURY 
IN THE SETTING OF ALCOHOL EXPOSURE – THE ROLE OF TNFα 
 
A. Introduction 
Alcohol use is widespread in the United States with more than half of 
Americans reporting alcohol consumption on a weekly basis (147).  It has long 
been known that chronic ethanol consumption can lead to development of a 
myriad of health effects spanning a variety of organs including the brain, gut, liver 
and lungs.  Indeed, the effects associated with chronic alcohol consumption have 
made alcohol the third leading risk factor globally for disease and disability (148) 
at a cost of more than $166 billion annually to treat the medical consequences of 
alcohol abuse (33). Despite the known health risks, alcohol consumption remains 
pervasive in today’s culture.  In toto, alcohol consumption is responsible for ~6% 
of all disability-adjusted life years (DALY) lost in the United States (149), most of 
which are attributable to alcohol-induced toxicity.   
The liver is well recognized as a major target of alcohol-induced organ injury.  
This is due in part to the high concentrations of alcohol reached in the portal 
blood as well as the detrimental effects of ethanol metabolism (e.g., oxidative 
stress).  Alcoholic liver disease (ALD) is actually a spectrum of disease states 
that include simple steatosis (fat accumulation), steatohepatitis, and in more 
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severe cases fibrosis and cirrhosis.  A major focus in ALD therapy is to treat the 
decompensation associated with end-stage ALD (i.e., cirrhosis).  Indeed, the 
sequelae of a failing liver (e.g., ascites, portal hypertension, and hepatorenal 
syndrome) are generally what causes death in end-stage ALD.  Although the 
successful treatment of these secondary effects prolongs the life of ALD patients, 
this therapy is only palliative; there are currently no therapies to halt or prevent 
the progression of ALD. 
Alcohol consumption can also contribute to lung damage.  In contrast to the 
liver, alcohol consumption does not appear to directly cause any overt pulmonary 
pathology; however, alcohol is known to exacerbate the severity of lung damage 
from other causes.  It has been estimated that up to 190,000 people suffer from 
acute lung injury (ALI) annually in the United States (52).  The risk of developing 
more severe forms of ALI such as acute respiratory distress syndrome (ARDS) is 
significantly higher in people who meet the diagnostic criteria for alcohol use 
disorders (53).  Whereas alcohol consumption does not cause overt pathology in 
the lung, studies have shown that experimental alcohol exposure can lead to 
subtle changes to this organ, which has been coined the ‘alcoholic lung 
phenotype.’  This effect of alcohol is characterized by dysregulated inflammatory 
response (55, 56), oxidative stress (58, 150), and tissue remodeling (59, 60).  
The dysregulated inflammatory response caused by alcohol in the lung is 
dependent on both the amount and duration of alcohol consumption and is 
suspected to be a key player in alcohol-related lung dysfunction (61).  The exact 
mechanisms that mediate the development of the alcoholic lung phenotype and 
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increased risk of ALI/ARDS remain unclear.  Better understanding of this 
complex process could identify potential therapeutic targets to treat or prevent 
alcohol-related lung dysfunction, such as ALI/ARDS. 
It is now clear that many human diseases are a multi-stage, multi-hit process; 
it is therefore not surprising that multiple cells within a target organ contribute to 
disease pathology.  Indeed, system level analyses of disease, and organ-organ 
interactions, are again gaining the attention of the research community.  Several 
studies indicate interdependence between liver and lung in organ pathology.  For 
example, mortality in ALI in the setting of severe hepatic disease is almost 100% 
(151).  In experimental models of liver injury, vascular permeability and leukocyte 
activation in lungs are increased (152).  Studies investigating the multi-organ 
effects of endotoxemia indicate that interaction between the liver and lung are not 
only likely, but may occur via alcohol-induced mediators (75) including TNFα 
(76), an inflammatory cytokine markedly increased in ALD (77).   
The purpose of this study was to characterize a model of concomitant liver 
and lung injury in the setting of chronic alcohol exposure.  It was hypothesized 
that chronic alcohol exposure acts as a first ‘hit’ that sensitizes these organs to a 
second inflammatory stimulus (e.g., bacterial lipopolysaccharide; LPS).  The 
parallel mechanisms of liver and lung injury in this ‘2-hit’ model were explored.  
Furthermore, the potential interdependence of liver and lung injury via systemic 





B. Experimental procedures 
1. Animals and treatments 
Animals were exposed to ethanol and/or LPS as described in Chapter II.  
Some animals also received the TNFα blocker etanercept as described in 
Chapter II. 
2. Histology 
Liver and lung tissue was stained with hematoxylin & eosin and chloroacetate 
esterase as described in Chapter II. 
3. Clinical Chemistry 
Serum levels of alanine aminotransferase (ALT) and aspartate 
aminostransferase (AST) were determined using standard kits as described in 
Chapter II. 
4. RNA isolation and real-time RT-PCR 
RNA was isolated from liver and lung tissue as described in Chapter II. Real 
time RT-PCR was performed for the genes TNFα, IL-6, IL-10, KC, MIP-2, and 
the endogenous control β-actin as described in Chapter II. 
5. Luminex 
Luminex technology was used to determine the levels of TNFα, IL-10, MIP-2, 
and KC in the plasma and BAL as described in Chapter II 
6. Statistical analysis 






Throughout the duration of dietary exposure, all mice gained ~0.6 g/week, with 
no differences between dietary and treatment groups.  In saline-treated mice fed 
control diet, liver weights (as percent of body weight) were 4.7± 0.1 g, whereas 
ethanol-fed mice had liver weights of 4.8 ± 0.2 g.  Liver weights in both groups 
were unchanged by LPS exposure. 
 
1. Ethanol-induced steatosis enhanced LPS-induced liver injury  
As expected, 6 wks exposure to EtOH-containing diet caused mild liver 
damage, characterized predominantly by microvesicular fat accumulation in 
midzonal regions of the liver (Figure 4.1A; H&E staining).  LPS administration to 
pair-fed animals increased the accumulation of inflammatory foci in liver.  
Feeding EtOH-containing diet increased the severity and frequency of 
necroinflammatory foci caused by LPS administration.  Plasma levels of alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST) were determined 
as indices of liver injury (Figure 4.1B).  Chronic ethanol exposure significantly 
increased ALT and AST levels in the plasma.  LPS alone did no significantly 
affected circulating levels of ALT or AST.  The combination of ethanol exposure 
and LPS significantly increased plasma ALT and AST 4 hours after LPS 
administration; 24 hours after LPS administration, AST values remained 
significantly elevated compared to controls  
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Figure 4.1: Effects of chronic ethanol pre-exposure on LPS induced liver 
injury and inflammation.   
 (A)  Representative photomicrographs of liver tissue after hematoxylin & eosin 
staining (200x; H&E) and chloroacetate-esterase staining (400x; CAE).  (B) 
Plasma levels of alanine-aminotransferase (ALT; black bars) and aspartate-
aminotransferase (AST; grey bars) were used as an index of liver injury.  (C) 
Quantitation of hepatic neutrophil content.  Data are shown as +/- SEM a, p < 

































































































In addition to hematoxylin and eosin staining, Figure 4.1 also shows staining for 
neutrophils using chloroacetate esterase staining (CAE staining).  Chronic 
ethanol exposure did not significantly affect neutrophil infiltration compared to 
their pair-fed counterparts (Figure 4.1A, right panels).  As was expected, LPS 
increased the number of neutrophils in the liver compared to vehicle controls.  
Ethanol pre-exposure dramatically enhanced neutrophil infiltration caused by 
LPS.   
 
2. Ethanol enhanced LPS-induced lung injury and inflammation 
In liver, LPS injection caused noticeable pathologic changes as early as 4 h 
after administration (Figure 4.1A).  Pathology in the lung tissue was also changed 
as early as 4 h as evidenced by inflammatory damage, however alveolar 
hemorrhage was not observed until the 24 hour timepoint (Figure 4.2).  At this 
timepoint, LPS increased areas of alveolar hemorrhage in the lung, which can be 
observed in H+E staining, as indicated by an increase in the number of red blood 
cells in the pulmonary interstitium (Figure 4.2A, left panels).  Hemorrhage was 
macro-heterogeneous, with some areas exhibiting a higher degree of 
hemorrhaging than others.  Analogous to findings in liver, EtOH enhanced LPS-
induced lung damage, as characterized by an increase in the frequency and 
severity of alveolar hemorrhage caused by LPS.  The increase in alveolar wall 
thickness caused by LPS also appeared to be more pronounced after ethanol 
exposure.  CAE staining of the lung tissue showed a significant increase in 
neutrophils in the lung tissue 4 h after LPS administration. Chronic ethanol  
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Figure 4.2: Effects of chronic ethanol pre-exposure on LPS induced lung 
injury and inflammation.   
(A)  Representative photomicrographs of lung tissue after hematoxylin & eosin 
staining (400x; H&E) and chloroacetate-esterase staining (400x; CAE). (B) Cell 
number in the bronchioalveolar lavage fluid (BALF).  (C) Quantitation of 
pulmonary neutrophil content.  Data are shown as +/- SEM a, p < 0.05 compared 


















































































exposure enhanced the effect of LPS at the 4 hour timepoint.  Incidentally, 24 
hours after LPS administration, neutrophil infiltration persisted, but was no longer 
significantly different between ethanol and pair-fed groups. 
 
3. Ethanol differentially alters cytokine/chemokine expression in the liver 
and lung  
The pathologic assessment of liver (Figure 4.1) and lung (Figure 4.2) 
indicates that chronic ethanol exposure enhanced the inflammation and damage 
caused by LPS in both organs caused by LPS.  To further characterize the 
mechanisms by which ethanol causes these effects, the mRNA expression of key 
inflammatory mediators (TNFα, IL-6, IL-10, PAI-1, MIP-2, and KC) were 
determined via real time RT-PCR (Figure 4.3A).  Chronic alcohol exposure alone 
caused no significant changes in mRNA expression of these select cytokines in 
either the liver or lung.  However, LPS administration alone significantly 
increased hepatic mRNA expression of TNFα, IL-6, IL-10, PAI-1, and MIP-2, with 
PAI-1 and MIP-2 being the most robustly induced; LPS did not significantly affect 
the hepatic mRNA expression of KC.  As expected, chronic ethanol exposure 
enhanced the increase in TNFα and IL-6 mRNA expression levels seen with LPS 
alone in the liver.   
Similar to the results seen in the liver, LPS administration alone increased the 
pulmonary mRNA expression of all mediators; however, the increase in TNFα 
was much less pronounced compared to liver and MIP-2 was the inflammatory 
mediator that was most robustly altered.  In contrast to the liver, chronic ethanol 
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Figure 4.3: Effect of chronic ethanol exposure on LPS-induced cytokine 
expression.  
(A)  Cytokine mRNA expression in the liver and lung at the four-hour LPS time 
point.  (B)  Inflammatory cytokine levels in the plasma and bronchoalveolar fluid 
(BALF) at the four-hour time point.  Data are shown as +/- SEM a, p < 0.05 






































































































































exposure did not significantly enhance the increase in TNFα expression seen 
with LPS alone.  However, ethanol did enhance the increases in IL-6, PAI-1, and 
MIP-2 mRNA caused by LPS in the lung, but the pattern of that enhancement 
differed from liver tissue.  Indeed the increase in MIP-2 caused by EtOH + LPS in 
the lung was >2-fold higher than observed in the liver.  Additionally, ethanol 
exposure significantly enhanced the increase in expression of KC in the lung, an 
effect not observed in liver tissue.   
The liver is the major contributor to the increase in inflammatory mediators in 
plasma in response to i.p. LPS administration (153).  Likewise, BALF contains 
inflammatory mediators produced by lung tissue.  The presence of the select 
mediators (TNFα, IL-10, MIP-2 and KC) in the plasma and BALF were therefore 
determined via Luminex assay (Figure 4.3B).  With the exception of IL-10 in the 
BALF, LPS treatment increased the levels of all four inflammatory mediators in 
the plasma and BALF.  In plasma, chronic ethanol exposure enhanced the 
increase in systemic IL-10 and TNFα caused by LPS, but did not significantly 
affect MIP-2 and KC.  In contrast, TNFα and IL-10 levels in the BALF were both 
insensitive to ethanol preexposure, but the increase in MIP-2 and KC caused by 
LPS administration was dramatically enhanced.   
 
4. Effect of etanercept on indices of injury and inflammation. 
Previous studies have established that TNFα production is critical for 
subsequent pulmonary chemokine (e.g., MIP-2 and KC) production and injury in 
experimental models of ARDS (154).  It is unclear, however, whether the source 
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of TNFα needs to be pulmonary or systemic in order to see this effect in the 
lungs (155).  Therefore, etanercept was used to deplete systemic TNFα, then 
measured the effects of etanercept on indices of damage and inflammation in the 
liver and lung. As seen in Figure 4, co-administration of etanercept during the 
course of the study partially protected against liver injury, as determined by AST 
levels  (Figure 4.4B), but did not affect steatosis or inflammation caused by 
ethanol or LPS (Figure 4.4A), respectively.  Etanercept administration decreased 
levels of freely soluble TNFα in response to the combination of LPS in the 
plasma and BALF, by 33% and 60%, respectively.  Interestingly, etanercept 
administration caused a 1.3-fold decrease in plasma MIP-2 levels which 
correlated with a decrease in MIP-2 mRNA expression in the liver.  Etanercept 
also caused decreased MIP-2 in the BALF as well as a 3.2-fold decrease in KC 
levels in the BALF.  The decrease in BALF KC levels correlated with a 3.5-fold 
decrease in pulmonary KC mRNA expression.   
 
D. Discussion 
It is now generally accepted that human disease can be a multi-stage, multi-
hit process in which various cells within a target organ contribute to disease 
pathology.   In addition to cell-cell interactions within a single organ, recent 
studies have begun to highlight the importance of more complex interactions, 
including those between multiple organs.  One example of such inter-organ 
interaction in the setting of alcohol exposure is the critical link between the 
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Figure 4.4: Etanercept protects against enhanced cytokine levels in the 
BALF without concomitant protection against liver injury.   
(A) Representative photomicrographs of liver tissue (200x; top) and lung tissue 
(400x; bottom) after hematoxylin & eosin staining.  (B) Fold change in indices of 
liver injury (ALT, AST), plasma and pulmonary cytokine levels, and mRNA 
expression in the liver and lung.  Data are shown as +/- SEM a, p < 0.05 
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intestine and the liver, or the gut-liver axis (156).  Indeed, a myriad of 
experimental and clinical studies have demonstrated that alcohol-induced gut  
dysbiosis and subsequent impairment of the gut barrier results in the release of 
gut-derived toxins (e.g. LPS) and endotoxemia (157-159).   Studies using 
antibiotics (137), germ-free mouse models (160), and probiotics (161) have 
confirmed that endotoxemia caused by alcohol consumption drives injury in 
experimental models of ALD.  Today, the gut-liver axis and enteric dysbiosis is a 
widely-accepted component in the development of ALD as well as other liver 
disease (156, 162).   
This group is particularly interested in potential interactions between the liver 
and lung, i.e. the liver-lung axis, in the context of alcohol exposure.  As 
mentioned in the introduction, liver disease is associated with increased 
incidence of acute lung injury and enhanced mortality.  These and other findings 
have suggested a potential interaction between the liver and lung that may 
represent an important aspect of the pathophysiology of acute lung injury, 
particularly in the setting of sepsis.  Bringham and collaborators tested the 
possible interaction between the liver and lung in a study performed in an in situ 
perfused piglet preparation (152).  Their model revealed that hypoxemia and 
pulmonary edema were only observed when the liver and lung circulations were 
connected.  Their results indicate that while endotoxemia could directly cause 
pulmonary vasoconstriction and leukocyte sequestration, interaction between the 
liver and lung was required for severe inflammatory response and oxidative injury 
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to the lung.  Additional studies have also shown that pulmonary injury induced by 
systemic endotoxin can be altered by mediators released from the liver (e.g. 
TNFα) (84, 152).  Unfortunately, few studies have investigated the potential 
interactions between the liver and lung in the setting of chronic alcohol exposure.  
Therefore the goal of this study was to characterize a model of concomitant liver 
and lung injury caused by LPS after chronic ethanol administration.  The Lieber-
Decarli model of chronic alcohol administration was chosen for this study 
because this model has been used previously to study effects of alcohol 
exposure on both the liver (163-167) and lung (62, 168, 169), albeit separately.  
Systemic LPS administration served as an inflammatory stimulus to induce 
hepatic inflammation and an ARDS-like phenotype in the lung.   
The effects of the Lieber-DeCarli rodent model of ethanol exposure on the 
liver is well-characterized and is predominated by hepatic steatosis (163).  Six 
weeks of exposure to the Lieber-Decarli diet does not cause overt liver injury or 
hepatic inflammation (163), but sensitizes the liver to other toxic stimuli.  In this 
study, LPS served as an inflammatory insult that induces hepatic inflammation 
and injury.  In this 2-hit model, alcohol pre-exposure enhanced liver injury and 
inflammation, which corroborates previous findings in this model.  Ethanol 
exposure has been shown to prime immune cells, including Kupffer cells, to 
release cytotoxic mediators including TNFα after stimulus (77, 170, 171).  In this 
study enhanced liver injury correlated with enhanced mRNA expression and 
plasma levels of TNFα in response to LPS, which previous studies have shown 
to be predominantly derived from Kupffer cells (172).  
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Acute lung injury is associated with increased release of pro-inflammatory 
cytokines (173) in the lung and neutrophil migration into the interstitium (174).  In 
this study, ethanol pre-exposure enhanced alveolar hemorrhage and neutrophil 
infiltration caused by LPS.  Studies have shown that neutrophil migration into the 
lung is at least partially mediated by the chemokines MIP-2 and KC (175-177).  
Indeed, both MIP-2 and KC have been linked to acute lung injury caused by 
systemic LPS (178, 179) by mediating neutrophil recruitment via activation of 
CXCR2 (180).  The work presented here shows that LPS-induced MIP-2 and KC 
expression in the lung was enhanced by ethanol exposure.  Furthermore, 
increases in these chemokines correlated with increased neutrophil recruitment.  
Interestingly, increased expression of MIP-2 and KC in the lung and BAL have 
been shown to be downstream of TNFα signaling (88), which was not enhanced 
by ethanol pre-exposure in the lung in our model.  In contrast, hepatic TNFα 
mRNA expression and systemic levels of TNFα were enhanced by the 
combination of ethanol + LPS. As mentioned previously, the role of Kupffer cell-
derived TNFα in liver injury is well recognized (181-183), however hepatic-
derived TNFα has also been shown to contribute to pulmonary injury.  A study by 
Kono et al demonstrated that depletion of hepatic Kupffer cells protected against 
pulmonary inflammation and injury and correlated with decreased TNFα 
expression (183).  These findings suggest that systemic inflammation mediated 
by increased release of TNFα by hepatic macrophages (i.e. Kupffer cells), may 
be partially responsible for driving pulmonary MIP-2 and KC expression, and 
subsequent pulmonary injury, as presented here.   
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In order to determine the role of systemic/hepatic TNFα in enhanced 
pulmonary injury, the effect of depleting systemic TNFα with etanercept was 
determined.  Etanercept is a fusion protein of the human p75 TNF receptor and 
the Fc portion of human IgG1.  This TNFα binding antibody has been approved 
by the FDA for treatment of rheumatoid arthritis and psoriasis.  In the work 
presented here, etanercept administration resulted in a 1.7 and 1.9 fold decrease 
in systemic and pulmonary TNFα levels, respectively, compared to animals that 
were exposed to ethanol + LPS in the absence of etanercept.  This incomplete 
blocking of systemic and pulmonary TNFα was likely due to the robust increase 
in TNFα caused by systemic LPS administration, particularly in the plasma; in 
fact, LPS administration caused more than a 10 fold increase in systemic TNFα 
levels compared to their vehicle-treated, ethanol-fed counterparts.  Despite the 
lack of complete TNFα knockdown, etanercept decreased TNFα levels in the 
plasma by >100 pg/mL.     
Etanercept under these conditions provided partial protection against 
inflammatory injury in the lung caused by the combination of ethanol and LPS.  
Etanercept administration blunted enhanced MIP-2 and KC levels in the lung, 
resulting in a 1.6 and 3.5 fold decrease, respectively.  These results support 
previous findings that TNFα signaling was upstream of enhanced MIP-2 
expression in experimental ARDS (184).  The authors of that study showed that 
TNFR1-/- mice were partially protected against increased MIP-2 expression in a 
model of acute lung injury (184).  Whereas the protective effect of TNFα 
depletion was significant, it was not complete.  Indeed, TNFα is likely one of 
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several factors that may contribute to the ‘alcoholic lung phenotype.  For 
example, PAI-1 has been linked to liver and lung injury (29, 50, 185) and was 
differentially affected by ethanol pre-exposure in this model.  Additionally, 
oxidative stress and transitional tissue remodeling are known to play important 
roles in liver injury and inflammation.  Therefore, complete protection against 
injury in either organ will likely require multiple interventions or an intervention 
that protects against multiple mechanisms of injury (i.e., Kupffer cell blockade).  
Nevertheless, these results establish a strong link between systemic TNFα and 
lung damage in this model of alcohol-enhanced ARDS.   
As mentioned above, the priming effect of ethanol on the hepatic 
inflammatory response is relatively well established.  In contrast, the effect of 
ethanol exposure on lung has predominantly focused on impaired bacterial 
clearance and subsequent increased susceptibility to pulmonary infections (186-
188).  Indeed, others have shown that ethanol preexposure impairs alveolar 
macrophage function and inflammatory cytokine release (168, 189, 190).  
However, there are two important differences between the current study and 
those that have reported decreased immune response after alcohol.  Specifically, 
the timing of LPS administration has been shown to play an important role in 
alcohol-induced liver injury.  Previous studies have shown that if LPS is 
administered during acute alcohol intoxication (or w/in 1 day of a bolus dose of 
alcohol), the hepatic inflammatory response is blunted.  In contrast, if LPS is 
given distal to alcohol intoxication, the inflammatory response is synergized 
(170).  Indeed, most studies that have documented a decrease in pulmonary 
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immune response in the context of alcohol exposure used acute models of 
intoxication in which LPS was administered within hours of alcohol exposure 
(186, 191-194).  Indeed, others have shown that chronic alcohol exposure can 
enhance pulmonary inflammation post-intoxication.  For example, a recent study 
by Liu et al showed that chronic ethanol exposure enhances the pulmonary 
inflammatory response caused by insult (195).  Additionally, Boe et al showed 
that chronic ethanol exposure enhances LPS-induced neutrophil migration, as 
was observed in the current study (196).  Therefore it is likely that the timing of a 
stimulus – whether during intoxication or distal to intoxication – plays a critical 
role in pulmonary response after alcohol exposure.  This timing effect could 
create a ‘perfect storm’ in the lung that clearance of infection is impaired during 
alcohol intoxication, but the inflammatory response and normal tissue damage 
caused by that infection is enhanced later.  Such a paradigm would explain the 
fact that ethanol exposure increases both the incidence of lung infections and the 
likelihood of developing ARDS in response to a lung infection in the human 
population.   
In conclusion, the current study characterizes a model of alcohol-induced liver 
and lung sensitization which enhances injury caused by systemic LPS.  These 
data suggest that the pulmonary response to ethanol is dependent on systemic 
release of TNFα, most likely from the liver (Figure 4.5).  Additionally, although 
ethanol pre-exposure enhanced both liver and lung inflammation, both organs 
experienced a unique pro-inflammatory cytokine profile indicating that similar, yet 
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Figure 4.5 Proposed mechanism of interdependent injury.   
 
This work supports the hypothesis that systemic TNFα plays an important role in 
enhanced pulmonary injury caused by the combination of chronic ethanol 
exposure and LPS.  The combination of ethanol and LPS caused significant 
increases in hepatic TNFα.  Interestingly, the combination of ethanol and LPS 
caused a significant increase in MIP-2 mRNA expression and protein levels in 
the lung tissue and BAL, respectively.  Previous studies have shown that MIP-2 
expression in the lung is driven, at least in part, by TNFα signaling.  The work 
here demonstrated that depleting systemic TNFα with etanercept partially 
protects against increased MIP-2 expression the lung.  This protection against 









distinct, mechanisms may be contributing to injury in these two organs.  Other 
studies have suggested that injury to the liver and lung may be linked, potentially 
via systemic mediators such as TNFα.  Enhanced MIP-2 and KC expression in 
the lung, without a concomitant increase in pulmonary TNFα further support a 
potential role for hepatic-derived TNFα as a mediator of pulmonary injury in this 
model.  Since etanercept is already approved for human use for treatment of 
rheumatoid arthritis and psoriasis, the translational value of these findings is 







ROLE OF THE EXTRACELLULAR MATRIX IN THE LIVER IN A MODEL OF 





The extracellular matrix (ECM) consists of a diverse group of proteins and 
sugars including collagens, glycoproteins and proteoglycans.  Together, these 
fibrous macromolecules create a scaffold that provides structure to tissues and a 
substratum for cells.  In addition to their structural role, these ECM components 
serve as signaling molecules via interactions with cell-surface receptors and 
impact cell-to-cell communication by binding and retaining soluble mediators 
including cytokines, chemokines, and growth factors (3).  Proteases and 
protease inhibitors present in the ECM serve as regulators of matrix degradation 
important for the maintenance of the ECM homeostasis as well as remodeling of 
the matrix composition in disease (2).  Together, the diverse range of the ECM 
components work bi-directionally with surrounding cells to create a dynamic and 
responsive microenvironment that regulates cell signaling, recruitment and tissue 
function.   
The role of the ECM is well established in the setting of chronic liver injury, 
such as alcoholic liver disease (ALD).  Indeed, robust changes in the hepatic 
ECM is the hallmark of later stages of liver disease (fibrosis and cirrhosis) which 
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are characterized by dramatic increases in collagen deposition (197).  Given the 
dominance of collagenous changes in the hepatic ECM during fibrosis/cirrhosis, 
many studies have focused on the mechanisms underlying changes in collagen 
deposition that lead to hepatic fibrosis.  However, the alterations of the hepatic 
ECM during fibrosis are much more diverse than simply an increase in collagen, 
and include changes in the deposition and distribution of a myriad of other ECM 
proteins (e.g., laminin and vitronectin), that may also contribute to fibrogenesis 
(48).   
Hepatic ECM changes are not only more diverse than simply changes to 
collagen, but also not only relegated solely to fibrogenesis per se.  Indeed, it is 
becoming increasingly understood that the hepatic ECM responds dynamically to 
stress.  For example, changes in the expression of ECM proteins such as 
fibronectin (28, 90), and fibrin (29, 49, 50) have been observed in models of 
hepatic inflammation.  Importantly, blocking these ECM changes blunts, at least 
in part, hepatic injury in these models.  Therefore, transitional changes to the 
ECM may contribute to early disease initiation and/or progression long before 
fibrosis phases of liver disease.   
Currently there exists a great need to characterize qualitative and 
quantitative changes in the ECM protein composition in earlier stages of disease 
that may be targeted for therapeutic benefit (198).  Although previous studies 
have shown that subtle changes in the ECM may contribute to the development 
of inflammatory liver injury, the research in this area has thus far been restricted 
to the hypothesis-driven study of single ECM components.  A more ‘omic 
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approach has been previously hampered by the difficulties associated with the 
low abundance and insolubility of many ECM proteins.  Therefore, a goal of this 
study was to develop a multi-step liver extraction that would allow for the 
enrichment and solubilization of ECM proteins.  A second goal of this work was 
to use proteomic analysis to determine global changes in the extracellular matrix 
in a model of inflammatory liver damage.   
 
 
B. Experimental procedures 
 
1. Animals and treatment 
 
Animals were exposed to ethanol and/or LPS as described in Chapter II 
 
2. ECM extraction 
 
Liver tissue was submitted to a 3-step extraction process that allows 
sequential isolation of loosely-bound extracellular proteins, cellular proteins, 
tightly bound extracellular proteins, and highly crosslinked, insoluble proteins to 
be differentially separated as described in Chapter II. 
3.  LC-MS analysis. 
Liver tissue extracts underwent liquid chromatography and mass spec 
analysis as described in Chapter II 
4. Analysis 
 
LC-MS data was analyzed as described in Chapter II 
 
5. Statistical analysis 
 








For this study, a previously described 3-step ECM fractionation method was 
adapted for use with mouse liver tissue (95-97).  The ECM isolation method was 
performed on hepatic tissue of from and a model of ASH which does not cause 
significant fibrosis.  Three sequential extraction steps were used in order to 
reduce cellular protein contamination and allow for greater resolution of low 
expressing ECM proteins (Figure 5.1).   
The first step of the extraction involved treatment with 0.5 M NaCl.  This step 
removes loosely-bound proteins by displacing polyionic interactions between 
proteins.  The ECM proteins extracted during this step likely include newly 
formed and/or degraded ECM components and ECM-binding proteins that are 
loosely associated with the matrix (e.g., proteins that bind to ECM 
glycosaminoglycans; (199).  Following NaCl extraction, the remaining liver tissue 
was decellularized using 1% SDS.  This step solubilizes cytoplasmic and nuclear 
membranes, allowing for the release of cellular proteins.  Decellularization was 
followed by a denaturing step with 4 M guanidine HCl (GnHCl) buffer (200).  
Following the denaturing extraction, an insoluble pellet enriched in highly 
insoluble, heavily cross-linked matrix proteins (i.e. type I collagens) remains (96).  
All three extracts as well as the insoluble pellet were subjected to enzymatic 
deglycosylation with chondroitinase ABC, endo-beta-galactosidase, and 
heparitinase II to remove the side chains chondroitin, keratin, and heparin sulfate 
of glycoproteins, respectively.  This step increases the chance of proper 
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Figure 5.1:  Scheme of extraction methodology.   
 
Liver tissue from pair-fed (control) animals and animals exposed to ethanol, LPS, 
or the combination of ethanol + LPS underwent increasingly vigorous extraction 
with a NaCl buffer, SDS buffer, and GnHCl buffer as described in Materials and 
























identification of proteoglycans by mass spectroscopy, which are infamous for 
being heavily post-translationally modified.   
1. Analysis of LC-MS data 
After LC-MS analysis (see Materials and Methods), Scaffold proteome 
software was used for visualization of the MS data.  Across the four experimental 
groups, the NaCl extract contained 588 proteins, the SDS extract contained 511, 
the GnHCl extract contained 585, and the pellet contained 322 proteins.  The 
Scaffold software allows classification of total proteins by gene ontology (GO) 
annotation.  When sorted by GO annotation, the NaCl contained 89 extracellular 
proteins, the SDS extract contained 63, GnHCl contained 84, and pellet 
contained 46 extracellular proteins.  Additional analysis was only performed on 
those proteins that were classified as extracellular proteins by GO annotation.  
The extracellular proteins identified by GO annotation were further categorized 
into four classes based on their role in the extracellular space as determined by a 
comprehensive literature search.  These four groups include class 1) 
glycoproteins and proteoglycans, class 2) other ECM-associated proteins class 
3) proteases and protease inhibitors and class 4) collagens.  If no record could 
be found supporting the hypothesis that a protein was associated with the ECM, 
the protein was placed into a fifth group, class 5) other proteins.  Table 5.1 shows 
a list of all the proteins from this study that were identified by GO annotation as 
extracellular, the classification of the extracellular proteins, and references 






Table 5.1:  Extracellular proteins 
 
Protein name Accession Number 
MW 
(kDa) ECM function Ref Presence of protein 
Proteoglycans and glycoproteins 
   
 
Con EtOH LPS 
EtOH 
+LPS 
Alpha-1-acid glycoprotein 1 A1AG1_MOUSE 24 Acute phase serum protein (201) NaCl  █ █ █ 
SDS     
GnHCl     
Pellet     
Alpha-2-HS-glycoprotein FETUA_MOUSE 37 Inhibitor of ECM mineralization (202) NaCl █ █ █ █ 
SDS     
GnHCl █ █ █ █ 
Pellet     
Arylsulfatase A ARSA_MOUSE 54 ECM structure (203) NaCl  █   
SDS     
GnHCl     
Pellet     
Beta-2-glycoprotein APOH_MOUSE 39 Coagulation, phospholipid 
binding 
(204) NaCl     
SDS     
GnHCl █ █ █ █ 
Pellet     
Biglycan PGS1_MOUSE 42 Regulation of collagen fibril 
formation, ECM-cell 
interactions 
(205) NaCl     
SDS     
GnHCl █ █ █ █ 
Pellet     
Corneodesmosin CDSN_MOUSE 54 Adhesive protein (206) NaCl     
SDS     
GnHCl     
Pellet █  █  
Cysteine-rich with EGF-like 
domain protein 2 
CREL2_MOUSE 38 Extracellular protein heavily 
glycosylated.  ECM 
function unknown 
(207) NaCl █ █ █ █ 
SDS     
GnHCl █ █ █ █ 
Pellet     





Decorin PGS2_MOUSE 40 ECM-cell interactions, ECM 
assembly 
(208) NaCl     
SDS     
GnHCl █ █ █ █ 
Pellet     
Dermatopontin DERM_MOUSE 24 ECM-cell interactions, ECM 
assembly 
(209) NaCl     
SDS     
GnHCl █ █ █ █ 
Pellet     
Dystroglycan DAG1_MOUSE 97 Matrix organization, basement 
membrane assembly 
(210) NaCl █ █ █ █ 
SDS     
GnHCl █ █ █  
Pellet     
Fibrinogen alpha chain E9PV24_MOUSE 87 Hemostasis, cell  signaling 
(fibrin(ogen) alpha chain) 
(211) NaCl   █ █ 
    SDS   █ █ 
    GnHCl  █ █ █ 
    Pellet    █ 
Fibrinogen beta chain FIBB_MOUSE 55 Hemostasis, cell  signaling (211) NaCl  █ █ █ 
SDS     
GnHCl     
Pellet     
Fibrinogen gamma chain FIBG_MOUSE 49 Hemostasis, fibrinogen 
polymerization 
(212) NaCl  █ █ █ 
SDS   █ █ 
GnHCl █ █ █ █ 
Pellet █   █ 
Fibronectin FINC_MOUSE 273 Scaffolding, ECM organization, 
regulation of ECM-cell 
interactions 
(213) NaCl     
SDS     
GnHCl █ █ █ █ 
Pellet     
Galectin-1 LEG1_MOUSE 15 Matrix  crosslinking, matrix 
organization 
(214) NaCl █ █ █  
SDS   █  
GnHCl █ █ █ █ 
Pellet     
Galectin-3-binding protein LG3BP_MOUSE 64 Cell-matrix adhesion (215) NaCl █ █ █ █ 
SDS  █ █ █ 
GnHCl █  █ █ 
Pellet     
          





          
Granulins GRN_MOUSE 63 Cell-matrix signaling (216) NaCl █ █ █ █ 
SDS █ █ █ █ 
GnHCl █ █ █ █ 
Pellet     
Haptoglobin HPT_MOUSE 39 Inhibition of collagen 
degradation, cell migration 
(217) NaCl █ █ █ █ 
SDS █ █ █ █ 
GnHCl █ █ █ █ 
Pellet  █ █ █ 
Insulin-like growth factor-
binding        protein 2 
IBP2_MOUSE 33 Binding/retainment of ILGF in 
the extracellular  space 
(218) NaCl     
SDS     
GnHCl █ █   
Pellet     
Insulin-like growth factor-
binding protein 4 
IBP4_MOUSE 28 Binding/retainment of ILGF in 
the extracellular  space 
(218) NaCl     
SDS     
GnHCl █ █   
Pellet     
Keratin, type I cytoskeletal 13 K1C13_MOUSE 48 Cell-matrix adhesion, cell 
migration 
(219) NaCl  █  █ 
SDS     
GnHCl     
Pellet   █  
Leucine-rich HEV 
glycoprotein 
Q91XL1_MOUSE 37 Cell-matrix adhesion (220) NaCl   █ █ 
SDS     
GnHCl     
Pellet     
Lumican LUM_MOUSE 38 Regulation of collagen fibril 
formation 
(221) NaCl     
SDS     
GnHCl █ █ █ █ 
Pellet █ █  █ 
Microfibrillar-associated 
protein 5 
MFAP5_MOUSE 18 Elastic fiber assembly, binding 
of fibrillin-1 and fibrillin-2 
(222) NaCl     
SDS     
GnHCl █   █ 
Pellet     
Fibrinogen alpha chain E9PV24_MOUSE 87 Hemostasis, cell  signaling 
(fibrin(ogen) alpha chain) 
(211) NaCl   █ █ 
SDS   █ █ 
GnHCl  █ █ █ 
Pellet    █ 





          
Ribonuclease inhibitor RINI_MOUSE 50 Extracellular inhibitor of 
angiogenin which can 
degrade BM 
(223) NaCl    █ 
SDS     
GnHCl     
Pellet     
Sulfated glycoprotein 1 SAP_MOUSE 61 Cell survival, cell signaling (224, 
225) 
NaCl     
SDS █ █ █ █ 
GnHCl █ █ █ █ 
Pellet █ █ █ █ 
Syndecan-4 SDC4_MOUSE 21 ECM organization, signal 
transduction, cell adhesion 
(226) NaCl  █ █ █ 
SDS █ █ █ █ 
GnHCl █ █ █ █ 
Pellet     
Tubulointerstitial nephritis  
     antigen-like 
TINAL_MOUSE 52 Protein binding - fibronectins, 
collagens 
(227) NaCl █ █ █ █ 
SDS     
GnHCl █ █  █ 
Pellet     
Vitronectin VTNC_MOUSE 55 ECM-cell signal transduction, 
cell adhesion 
(228) NaCl █ █ █ █ 
SDS     
GnHCl  █ █ █ 
Pellet     
Other ECM-associated proteins 
 
 
Con EtOH LPS 
EtOH 
+LPS 
14-3-3 protein epsilon 1433E_MOUSE 29 Protein binding (229) NaCl █ █ █ █ 
SDS     
GnHCl     
Pellet   █  
14-3-3 protein gamma 1433G_MOUSE 28 Protein binding (229) NaCl █ █ █ █ 
SDS     
GnHCl  █ █ █ 
Pellet     
14-3-3 protein sigma 1433S_MOUSE 28 Protein binding (229) NaCl     
SDS     
GnHCl     





14-3-3 protein zeta/delta 1433Z_MOUSE 28 Protein binding (229) NaCl █ █ █ █ 
SDS  █ █ █ 
GnHCl     
Pellet   █  
Actin, cytoplasmic 1 ACTB_MOUSE 42 Cortical cytoskeleton (230, 
231) 
NaCl █ █ █ █ 
SDS █ █ █ █ 
GnHCl     
Pellet █ █ █ █ 
Actin, cytoplasmic 2 ACTG_MOUSE 42 Cortical cytoskeleton (230, 
231) 
NaCl     
SDS     
GnHCl █ █ █ █ 
Pellet     
Alpha-2-macroglobulin 
receptor-    
     associated protein 
AMRP_MOUSE 42 Protein binding, soluble 
mediator internalization 
(232) NaCl █ █ █  
SDS  █ █ █ 
GnHCl █ █ █ █ 
Pellet     
Alpha-actinin-4 ACTN4_MOUSE 105 Focal adhesion,  cell adhesion (233, 
234) 
NaCl █ █ █ █ 
SDS     
GnHCl     
Pellet   █  
Annexin A1 ANXA1_MOUSE 39 ECM binding, fibrinolysis (235) NaCl    █ 
SDS     
GnHCl █    
Pellet     
Annexin A2 ANXA2_MOUSE 39 ECM binding, fibrinolysis (236) NaCl █ █ █ █ 
SDS █ █   
GnHCl     
Pellet █ █ █ █ 
Annexin A5 ANXA5_MOUSE 36 ECM binding (collagen) (237) NaCl █ █ █ █ 
SDS     
GnHCl     
Pellet     
Apolipoprotein A-I APOA1_MOUSE 31 ECM binding (collagen, 
fibronectin) 
(238) NaCl █ █ █ █ 
SDS █ █ █ █ 
GnHCl █ █ █ █ 
Pellet █ █ █ █ 
          





          
Apolipoprotein A-IV APOA4_MOUSE 45 Lipid metabolism (239) NaCl █ █ █ █ 
SDS   █ █ 
GnHCl █  █ █ 
Pellet █ █  █ 
Apolipoprotein E APOE_MOUSE 36 Lipid metabolism, cell signaling (240) NaCl █ █ █ █ 
SDS     
GnHCl █ █  █ 
Pellet     
Apolipoprotein O-like APOOL_MOUSE 29    NaCl █ █ █ █ 
SDS  █ █ █ 
GnHCl     
Pellet     
Beta-2-microglobulin B2MG_MOUSE 14 Protein binding, cell-ECM 
interaction 
(241) NaCl     
SDS █ █ █ █ 
GnHCl █ █ █ █ 
Pellet     
Calreticulin CALR_MOUSE 48 Protein binding (collagens, 
laminin)  
(242) NaCl █ █ █ █ 
SDS █ █ █ █ 
GnHCl █ █ █ █ 
Pellet     
Calumenin CALU_MOUSE 37 Pprotein binding, stabilization of 
fibulin-1 
(243) NaCl █ █ █ █ 
SDS     
GnHCl     
Pellet █ █  █ 
Carbonic anhydrase 2 CAH2_MOUSE 29 pH regulation of ECM (other 
isozymes) 
(244) NaCl █ █ █ █ 
SDS     
GnHCl     
Pellet     
Ceruloplasmin CERU_MOUSE 121 Iron, copper binding (245) NaCl  █ █ █ 
SDS     
GnHCl     
Pellet     
Chitinase-like protein 3 CHIL3_MOUSE 44 ECM turnover (246) NaCl   █ █ 
SDS     
GnHCl     
Pellet     





          
Clusterin CLUS_MOUSE 52 Extracellular protein chaperone (247) NaCl     
SDS   █ █ 
GnHCl  █ █ █ 
Pellet     
Cofilin-1 COF1_MOUSE 19 Cortical cytoskeleton,  cell 
motility 
(248) NaCl     
SDS     
GnHCl █ █ █ █ 
Pellet     
C-reactive protein CRP_MOUSE 25 Protein binding (fibronectin) (249) NaCl █ █ █ █ 
SDS  █ █  
GnHCl     
Pellet     




NaCl █ █ █ █ 
SDS     
GnHCl   █  
Pellet     
Endoplasmin ENPL_MOUSE 92 Soluble mediator (TLR  
signaling) 
(252) NaCl █ █ █ █ 
SDS █ █ █ █ 
GnHCl     
Pellet █ █ █ █ 
Estradiol 17-beta-
dehydrogenase 12 
DHB12_MOUSE 35 Protein binding (heparin, 
fibronectin, collagen) 
(253) NaCl     
SDS █ █   
GnHCl     
Pellet     
Ferritin heavy chain FRIH_MOUSE 21 Cell  migration (254) NaCl █ █ █ █ 
SDS █ █ █ █ 
GnHCl  █ █ █ 
Pellet     
Ferritin light chain 1 FRIL1_MOUSE 21 Cell migration (254) NaCl █ █ █ █ 
SDS █ █ █ █ 
GnHCl █ █ █ █ 
Pellet     
Glucose-6-phosphate 
isomerase 
G6PI_MOUSE 63 Cell motility (255) NaCl █ █ █ █ 
SDS     
GnHCl     
Pellet     





          
Hepatoma-derived growth 
factor 
HDGF_MOUSE 26 Decreted heparin-binding 
growth factor 
(256) NaCl █ █ █ █ 
SDS     
GnHCl █ █ █ █ 
Pellet     
High mobility group protein 
B1 
HMGB1_MOUSE 25 Heparin binding, cytokine (257, 
258) 
NaCl █ █ █ █ 
SDS     
GnHCl █ █ █ █ 
Pellet     
High mobility group protein 
B2 
HMGB2_MOUSE 24 Heparin binding, cytokine (257, 
258) 
NaCl  █ █ █ 
SDS     
GnHCl     
Pellet     
Lumican LUM_MOUSE 38 Regulation of collagen fibril 
formation 
(221) NaCl   █ █ 
SDS     
GnHCl     
Pellet     
Moesin MOES_MOUSE 68 Cell cortex organization (259) NaCl █ █ █ █ 
SDS     
GnHCl     
Pellet     
Myosin-9 MYH9_MOUSE 226 Cell migration, cortical actin 
organization 
(260) NaCl   █ █ 
SDS █ █ █ █ 
GnHCl █ █ █ █ 
Pellet     
Neutrophil gelatinase-
associated  
      lipocalin 
NGAL_MOUSE 23 ECM remodeling (modulation of 
MMP9 activity) 
(261) NaCl   █ █ 
SDS     
GnHCl   █ █ 
Pellet     
Nucleobindin-2 NUCB2_MOUSE 50 Matrix maturation (262) NaCl     
SDS     
GnHCl    █ 
Pellet     
Peptidyl-prolyl cis-trans  
     isomerase A 
PPIA_MOUSE 18 Matrix assembly of hensin (263) NaCl █ █ █ █ 
SDS █ █ █ █ 
GnHCl █ █ █ █ 
Pellet █  █  





          
Pro-cathepsin H CATH_MOUSE 37 Matrix degradation (264) NaCl █ █ █ █ 
SDS     
GnHCl     
Pellet     
S100-A13 S10AD_MOUSE 11 Calcium binding (265) NaCl █ █ █ █ 
SDS     
GnHCl     
Pellet     
S100-A9     NaCl  █ █ █ 
SDS █ █ █ █ 
GnHCl  █ █ █ 
Pellet     
Serum amyloid A-1  SAA1_MOUSE 14 Cell adhesion (266) NaCl   █ █ 
SDS     
GnHCl  █ █ █ 
Pellet   █ █ 
Serum amyloid A-2 SAA2_MOUSE 14 Cell adhesion (266) NaCl   █ █ 
SDS     
GnHCl  █ █ █ 
Pellet    █ 
Serum amyloid A-3 SAA3_MOUSE 14 Cell adhesion (266) NaCl     
SDS     
GnHCl   █ █ 
Pellet     




NaCl    █ 
SDS     
GnHCl     
Pellet     
Superoxide dismutase [Cu-
Zn] 
SODC_MOUSE 16 Protein binding 
(heparin/heparan sulfate,  
type 1 collage) 
(269) NaCl █ █ █ █ 
SDS █ █ █ █ 
GnHCl █ █ █ █ 
Pellet █ █ █ █ 
Thioredoxin THIO_MOUSE 12 Soluble mediator 
(immunomodulatory 
cytokine) 
(258) NaCl █ █ █ █ 
SDS     
GnHCl █ █ █ █ 
Pellet █ █ █ █ 






          
Tubulin beta-5 chain TBB5_MOUSE 50 Microtubule formation, modified 
via ECM interactions 
(231) NaCl     
SDS     
GnHCl █ █ █ █ 
Pellet     
UPF0556 protein C19orf10 
homolog 
CS010_MOUSE 18 Soluble mediator (cytokine) (270) NaCl █ █ █ █ 
SDS     
GnHCl     
Pellet     
Vimentin VIME_MOUSE 54 Microtubule formation  (271) NaCl █ █ █ █ 
SDS     
GnHCl █ █ █ █ 
Pellet █ █  █ 
Vitamin D-binding protein VTDB_MOUSE 54 Vitamin D binding (272) NaCl █ █ █ █ 
SDS █ █ █ █ 
GnHCl █ █ █ █ 
Pellet     
Proteases and protease inhibitors 
   
 
Con EtOH LPS 
EtOH 
+LPS 
Alpha-1-antitrypsin 1-1 A1AT1_MOUSE  46 Inhibition of ECM proteases; 
inhibition of trypsin 
(273) NaCl █ █ █  
SDS     
GnHCl  █ █ █ 
Pellet █ █  █ 
Alpha-1-antitrypsin 1-4 A1AT4_MOUSE 46 Inhibition of ECM proteases; 
inhibition of trypsin 
(273) NaCl █ █ █ █ 
SDS █ █ █ █ 
GnHCl     
Pellet     
AMBP AMBP_MOUSE 39 Precursor of protein HC 
(protein-ECM interactions) & 
bikunin (protease inhibitor),  
(274-
276) 
NaCl   █ █ 
SDS     
GnHCl █ █ █ █ 
Pellet     
Alpha-2-macroglobulin A2M_MOUSE  166 Inhibition of ECM proteases, 
inhibition of ADAMTS-7 
and ADAMTS-12 
(277) NaCl █ █  █ 
SDS     
GnHCl     






Antithrombin-III ANT3_MOUSE 52 Inhibition of ECM proteases, 
inhibition of thrombin 
(278) NaCl █ █ █ █ 
SDS █ █ █  
GnHCl  █  █ 
Pellet     
Cathelin-related 
antimicrobial peptide 
CRAMP_MOUSE 20 Inhibition of ECM proteases, 
inhibition of cathepsin L-
cysteine protease activity 
(279) NaCl  █ █ █ 
SDS   █ █ 
GnHCl  █ █ █ 
Pellet     
Cathepsin B CATB_MOUSE 37 ECM degradation (264) NaCl █ █ █ █ 
SDS    █ 
GnHCl     
Pellet     
Cathepsin D CATD_MOUSE  45 ECM degradation, activation of 
cathepsin B 
(280) NaCl █ █ █ █ 
SDS     
GnHCl    █ 
Pellet     




NaCl █ █ █ █ 
SDS  █ █ █ 
GnHCl   █ █ 
Pellet     
Complement C3 CO3_MOUSE 186 Activation of complement 
system 
(283) NaCl   █ █ 
SDS █ █ █ █ 
GnHCl     
Pellet     
Dipeptidyl peptidase 4 DPP4_MOUSE 87 Protein cleavage (cytokines, 
chemokines), protein 
binding (collagen) 
(284) NaCl     
SDS   █ █ 
GnHCl  █   
Pellet     
Ectonucleoside triphosphate 
diphosphohydrolase 5 
ENTP5_MOUSE 47 Hydrolysis of extracellular ATP (285) NaCl  █   
SDS     
GnHCl     
Pellet     
Fetuin-B FETUB_MOUSE 43 Cysteine protease inhibitor, 




NaCl █ █ █ █ 
SDS     
GnHCl     
Pellet     
          






          
Gelsolin GELS_MOUSE 86 Actin filament capping (288) NaCl █ █ █ █ 
SDS     
GnHCl   █ █ 
Pellet     
Ectonucleoside triphosphate 
diphosphohydrolase 5 
ENTP5_MOUSE  47 Hydrolysis of extracellular 
ATP/ADP (signaling) 
(286) NaCl  █  █ 
SDS     
GnHCl     
Pellet     
Hemopexin HEMO_MOUSE 51 Heme binding (289) NaCl █ █ █ █ 
SDS     
GnHCl █ █ █ █ 
Pellet     
Insulin-degrading enzyme IDE_MOUSE  118 Metalloendopeptidase (290) NaCl     
SDS     
GnHCl     
Pellet   █  
Inter alpha-trypsin inhibitor, 
heavy chain 4 
ITIH4_MOUSE 100 Chain of ITI (protease inhibitor) (291) NaCl   █  
SDS     
GnHCl     
Pellet     
Lysozyme C-1 LYZ1_MOUSE 17 Antibacterial, hydrolysis of β-1, 
4-glycosidic linkages 
(292) NaCl     
SDS     
GnHCl     
Pellet █ █ █ █ 
Lysozyme C-2 LYZ2_MOUSE 17 Antibacterial, hydrolysis of β-1, 
4-glycosidic linkages 
(292) NaCl  █ █ █ 
SDS     
GnHCl     
Pellet     
Murinoglobulin-1 MUG1_MOUSE 165 Protease  inhibitor (293, 
294) 
NaCl █ █ █ █ 
SDS     
GnHCl █ █ █ █ 
Pellet     
Myeloid bactenecin (F1) O08692_MOUSE 19 Cysteine protease inhibitor (295) NaCl  █ █ █ 
SDS  █ █ █ 
GnHCl  █ █ █ 
Pellet     






          
Phosphatidylethanolamine-
binding protein 1 
PEBP1_MOUSE 21 Serine protease inhibitor (296) NaCl █ █ █ █ 
SDS  █ █ █ 
GnHCl █ █ █ █ 
Pellet     
Plasminogen PLMN_MOUSE 91 Precursor of plasmin (serine 
protease) 
(297) NaCl     
SDS     
GnHCl  █ █ █ 
Pellet     
Probable carboxypeptidase 
PM20D1 
P20D1_MOUSE 56    NaCl █ █ █ █ 
SDS  █ █ █ 
GnHCl     
Pellet     
Serpinb9 O08797_MOUSE 42 Serine protease inhibitor, 
granzyme inhibitor) 
(298) NaCl    █ 
SDS     
GnHCl     
Pellet     
Serine protease inhibitor 
A3K 
SPA3K_MOUSE 47 Serine protease inhibitor,  
chymotrypsin inhibitor 
(299) NaCl █ █ █ █ 
SDS   █ █ 
GnHCl     
Pellet     
Serine protease inhibitor 
A3N 
SPA3N_MOUSE 47 Serine protease inhibitor,  
chymotrypsin inhibitor 
(299) NaCl   █ █ 
SDS     
GnHCl     
Pellet     
Serpin B5 SPB5_MOUSE 42 Serine protease inhibitor,  (299) NaCl     
SDS     
GnHCl     
Pellet   █  
Thioredoxin THIO_MOUSE 12 Activation of transglutaminase (300) NaCl     
SDS █ █ █ █ 
GnHCl     
Pellet     





NaCl     
SDS █ █ █ █ 
GnHCl █ █ █ █ 
Pellet     







     Con EtOH LPS 
EtOH 
+LPS 





NaCl █ █ █ █ 
SDS     
GnHCl     
Pellet     
Collagen alpha-1(I) chain CO1A1_MOUSE 138 Component of collagen fibrins (303) NaCl     
SDS █ █ █ █ 
GnHCl █ █ █ █ 
Pellet █ █ █ █ 
Collagen alpha-1(III) chain CO3A1_MOUSE 139 Component  of collagen fibrils (303) NaCl     
SDS     
GnHCl █ █ █ █ 
Pellet █ █ █ █ 
Collagen alpha-1(IV) chain CO4A1_MOUSE 161 Component of collagen network (303) NaCl     
SDS     
GnHCl █ █   
Pellet █ █ █ █ 
Collagen alpha-1(V) chain CO5A1_MOUSE 184 Fibrillogenesis, crosslinking (303) NaCl     
SDS     
GnHCl     
Pellet  █   
Collagen alpha-2(I) chain CO1A2_MOUSE 130 Component  of collagen fibrils 
(contains collage-like 
domain) 
(303) NaCl     
SDS █   █ 
GnHCl █ █ █ █ 
Pellet █ █ █ █ 
Collagen alpha-2(IV) chain CO4A2_MOUSE 167 Component of collagen network (303) NaCl     
SDS     
GnHCl     
Pellet  █  █ 
Collagen alpha-2(V) chain CO5A2_MOUSE 145 Fibrillogenesis, crosslinking (303) NaCl     
SDS     
GnHCl  █   
Pellet █ █  █ 
Mannose binding protein MBL2_MOUSE 26 soluble pattern recognition  
receptor 
(305) NaCl     
SDS     
GnHCl █ █ █ █ 






Extracellular - ECM interactions unknown         
60  heat shock protein, 
mitochondrial 
CH60_MOUSE 61   
78  glucose-regulated 
protein 
GRP78_MOUSE 72   
Aminoacyl tRNA synthase 
complex-interacting 
multifunctional  
      protein 1 
AIMP1_MOUSE 34   
Arginase-1 ARGI1_MOUSE 35   
BolA-like protein 1 BOLA1_MOUSE 14   
BolA-like protein 3 BOLA3_MOUSE  12   
Carboxylesterase 1C EST1C_MOUSE 61   
Clathrin heavy chain 1 CLH1_MOUSE 192   
Epididymal secretory protein 
E1 
NPC2_MOUSE 16   
Group XIIB secretory 
phospholipase A2-like 
protein 
Q8VC81_MOUSE 22   
Heat shock cognate 71  
protein 
HSP7C_MOUSE  71   
Hepcidin HEPC_MOUSE 9   
Hypoxia up-regulated protein 
1 








IIGP1_MOUSE 48   
Lactotransferrin TRFL_MOUSE 78   
Macrophage migration 
inhibitory factor 
MIF_MOUSE 13   
Major urinary protein 12 A2CEK7_MOUSE 21   
Major urinary protein 17 MUP17_MOUSE 21   
Major urinary protein 20 MUP20_MOUSE 21   
Major urinary protein 3 MUP3_MOUSE  21   
Major vault protein MVP_MOUSE 96   
Monocyte differentiation 
antigen CD14 
CD14_MOUSE 39   
Multiple coagulation factor 
deficiency protein 2 
homolog 
MCFD2_MOUSE 16   
Myeloperoxidase PERM_MOUSE 81   
Nuclease-sensitive element-
binding protein 1 
YBOX1_MOUSE 36   
Polymeric immunoglobulin 
receptor 
PIGR_MOUSE 85   






Protein CREG1 CREG1_MOUSE 24   
Protein Gm20425 E9Q035_MOUSE  108   
Pyruvate kinase PKM KPYM_MOUSE 58   
RNA binding motif protein, 
X-linked-like-1 
RMXL1_MOUSE 42   
Serotransferrin TRFE_MOUSE 77   




PON1_MOUSE 40  
Translationally-controlled 
tumor protein 
TCTP_MOUSE 19   
UPF0369 protein C6orf57 
homolog 
CF057_MOUSE 12   
Xanthine 
dehydrogenase/oxidase 
XDH_MOUSE 147   









2. 3-step serial extraction creates 4 extracts with distinct protein 
profiles 
For initial analysis, the ECM proteins present in each of the four extracts 
from control animals was compared (Figure 5.2, top) without regard to protein 
classification.  Each extract had a unique extracellular protein profile consisting of 
not only ECM proteins that were shared among all four extracts (7), but also 
proteins unique to particular extracts.  Indeed, there were 16, 3, 15, and 7 
proteins unique to the NaCl, SDS, GnHCl, and pellet fractions, respectively in 
livers from control animals.  These results indicate that the extraction approach 
was effective at separating the proteins. 
When ECM proteins were compared between treatment groups, 
interesting patterns of protein presence in the extracts were revealed (Figure 5.3, 
lower).  For example, some proteins (e.g., plasminogen), if present, located 
consistently to the same extraction fraction across the treatment groups.  The 
effect of treatments on other proteins was more complex than the simple 
presence and absence.  For example, whereas annexin A1 was found in the 
insoluble pellet in samples from control animals, it was absent in the liver from 
animals exposed to ethanol or LPS alone; however, the combination of ethanol 
and LPS caused this protein to accumulate in the NaCl fraction.  Likewise, 
although fibrin(ogen) gamma chain peptides were found in all treatment groups, 
the location of these signals was unique to each treatment condition.  These  
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Figure 5.2: Liver extracts have unique protein profiles based on fraction 
type and experimental group.   
The number of proteins unique to or shared by all four extractions of pair-fed 
animals is shown (A).  Bubble graphs are used to show presence of 
plasminogen, annexin A1 and fibrin(ogen) gamma chain across the four extracts 










changes likely represent differences in the synthesis, degradation and/or maturity 
of the ECM proteins. 
3. Qualitative changes to the ECM proteome in response to stress 
The highest abundance of ECM was found in the GnHCl fraction of the 
control liver, which was closely followed by the NaCl fraction.  Of the proteins in 
the NaCl and SDS extracts the majority were ECM-associated proteins (class 2; 
Figure 5.3); this effect was expected as these are generally loosely associated 
with the extracellular matrix and are easily solubilized.  Additionally, the low 
abundance of collagens (class 3) in the NaCl and SDS fractions was not 
surprising as collagens are often tightly cross-linked and require denaturing 
conditions for solubilization.  As expected, the denaturing conditions created by 
GnHCl more than doubled the number of proteoglycans and glycoproteins in the 
GnHCl extract compared to the NaCl and SDS fractions.  The number of 
collagens in the GnHCl extract were also dramatically increased compared to the 
NaCl and SDS fractions.  The pellet fraction contained the fewest proteins of all 
four extracts; this fraction has the greatest number of collagens (8) which are 
known to be highly cross-linked to the point of insolubility (306).  These results 
indicate that the 3 step extraction process was successful in separating and 
enriching the ECM proteins. 
Exposure to ethanol and LPS, alone or combined, did not change the 
general pattern of proteins found in the various extracts (Figure 5.3), but both 
tended to increase the number of ECM proteins.  For example, ethanol exposure 
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Figure 5.3: Ethanol and LPS cause dynamic changes in the matrisome.   
 
Each row represents a separate extract and each column represents a separate 
experimental group comparison.  In the left column, the number of proteins 
unique to the control (blue) or ethanol (yellow) groups and the number of proteins  
shared between the two experiment groups (green) in toto (Venn diagram) or 
separated by protein class (stacked bar graph) are shown.  Similarly, in the right 
column, Venn diagrams show the total number of proteins unique to control 
(blue) or LPS (yellow) group and shared between these two groups (green) and 
stacked bar graphs show changes in protein number by protein class.  The size 








caused a net increase in the number of ECM proteins by ~22%.  These changes 
were spread across the first 3 protein classes [(1) proteoglycans and 
glycoproteins, (2) ECM associated proteins, and (3) protease and protease 
inhibitors] with the NaCl, SDS and GnHCl extracts all increasing to a similar 
extent.  The least responsive protein class were the collagens (class 4), which 
did not show a net increase with ethanol or LPS exposure.  Likewise, the pellet 
fraction responded the least dynamically to ethanol or LPS exposure, and 
actually showed a net loss in total proteins.  Figure 5.4 (left panels), shows the 
distribution of the proteins in the various extracts between all 4 treatment groups. 
In addition to proteins that changed in their extraction pattern in response 
to ethanol (e.g., see Figure 5.2, lower panel), there were 22 proteins whose 
presence was unique to ethanol exposure compared to control; these include 
fibrin(ogen) α and β chains, cytokeratin 13, vitronectin, plasminogen, high 
mobility group protein B2, and collagens IVα2 and Vα2.  Likewise, LPS exposure 
caused the appearance of several proteins that were unique compared to control.  
Eighteen of these proteins were shared with ethanol exposure (e.g., fibrin(ogen) 
α and β chains, cytokeratin 13, vitronectin, plasminogen, high mobility group 
protein B2, and collagen IVα2), but also 14 that were unique to LPS compared to 
ethanol, including serpin B5 (maspin), serine protease inhibitor A3N (Serpin 
A3N), and CXC motif chemokine 9 (CXCL9). 
Previous work has shown that ethanol pre-exposure sensitizes the liver to 
inflammatory injury caused by a second insult (i.e. LPS) (170, 307).  
Furthermore, previous studies have suggested that changes in the ECM 
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composition can contribute to the sensitizing effect of ethanol pre-exposure (29, 
50, 308).  In this study, the combination of chronic ethanol exposure and a 
second hit of LPS caused unique changes in the ECM protein profile of the liver.  
Indeed, the combination of EtOH + LPS resulted in the appearance of 4 unique 
proteins that were not present in livers from animals exposed to either ethanol or 
LPS alone, including serum amyloid P and serpine B9.   
4. Quantitative changes to the extracellular proteome caused by stress.  
The composition of extracellular environment is tightly regulated and drastic 
changes, such as the presence or absence of ECM proteins, can produce 
functional changes in the surrounding tissue.  Therefore, it was not surprising 
that the presence of the majority (73 proteins) of the extracellular matrix proteins 
was not altered by any exposure regardless of fraction type.  However, several 
proteins that did not change qualitatively changed in abundance.  In order to 
understand better the more subtle changes on the expression of extracellular 
proteins in the four fractions, quantitative changes in the expression that were not 
changed qualitative was determined (Figure 5.4, right panels). 
Several proteins change quantitatively in response to ethanol and/or LPS 
exposure relative to control animals in the livers.  Notable (>4-fold increase) 
changes caused by LPS included ferritin heavy chain (15-fold increase) in the 
NaCl fraction, haptoglobin and myosin-9 (11- and 9-fold, respectively) in the SDS 
fraction, and fibrinogen γ chain and haptoglobin (14- and 7-fold, respectively) in 
the GnHCl fraction.  Notable changes caused by ethanol include myosin-9 (6- 
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Figure 5.4: Liver extracts show quantitative changes in the matrisome. 
 
Venn diagrams (left column) show all proteins within an extract and indicate the 
number that are shared between or that are unique to the four experimental 
groups.  Bubble plots (right column) show quantitative changes in protein 
expression of proteins that were shared by all four experimental groups.  The 
bubble plots show fold change in protein expression caused by LPS (y-axis), 
ethanol (x-axis), and the combination of ethanol + LPS (bubble size).  Each 












fold) and cysteine-rich with EGF-like domain protein 2 (CREDL2; 6-fold) in the 
SDS fraction.  As was observed for qualitative analysis (Figure 5.3), the pellet 
fraction was the most stable of the fractions with very few changes in the 
expression level of ECM proteins.   
Some proteins responded to the combination of ethanol and LPS 
exposure differentially than a simple additive effect.  For example, although LPS 
alone did not change endoplasmin levels and ethanol only increased it 3-fold, the 
combination of ethanol and LPS increased this protein 11-fold in the NaCl 
fraction.  A similar effect was seen on granulin expression in the SDS fraction, 
which was increased by 5-fold by LPS + ethanol despite no effect by ethanol 
alone and only a 2-fold increase by LPS.  Additionally, although both LPS and 
ethanol alone increased CRELD2 the combination of ethanol + LPS actually 
decreased the levels in the SDS fraction.  In the GnHCl fraction, proteins that 
were differentially regulated by the combination of ethanol and LPS include 




The aim of this work was to develop and characterize a method of hepatic 
ECM protein extraction and analysis that would provide both the sensitivity to 
identify low expression proteins and the power to observe global changes in the 
ECM using proteomics.  As mentioned in the Introduction, the study of the 
hepatic ECM proteome (i.e., matrisome) has largely been ‘collagenocentric’ and 
‘fibrisocentric – that is, centered on the dramatic increase in collagen deposition 
during fibrosis, a quasi-permanent scarring of the organ.  However, the 
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matrisome of the healthy and diseased liver is significantly more diverse than 
collagen ECM.  Indeed, studies have shown that in addition to collagen, laminin 
(306) and vitronectin (309, 310) are also increased during fibrogenesis.  
Furthermore, proteomic-based studies in other organs haves demonstrated that 
the matrisome responsds dynamically in composition after insult (95-97).  
Previously, this group showed that fibrin ECM accumulation correlates with 
inflammatory liver injury in several models, and may well play a causal role (29).  
Additionally, Gillis et al. have shown a similar role for fibronectin ECM in 
experimental ALD (28).  However, little is known about global changes in the 
hepatic ECM during inflammatory liver injury.   
Global changes in the ECM may mediate tissue function via mechanisms 
that fall generally into three categories, including physical, biochemical, and 
signaling.  Physical properties of the ECM include the matrix topography, 
organization, and crosslinking (2).  These physical properties support the 
structural role of the ECM, but can also allow regulation of cell migration both by 
serving as a physical barriers or enhancer to that function (26).  For example, 
fibrin matrices are permissive to chemotaxis and activation of monocytes and 
leukocytes (311, 312).  Physical changes in the ECM can cause tissue rigidity 
resulting in reduced organ function.  Although such physical changes to the ECM 
can of course indirectly influence the biochemistry of the liver (e.g., hemostasis-
induced hypoxia), changes to the mastrisome can also directly cause 
biochemical changes that are independent of structural changes.  For example, 
ECM components can facilitate interactions between ligands and receptors (313), 
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bind and retain chemokines (3), and regulate activation of growth factors (i.e. 
TGFβ, (3).  ECM molecules also can serve directly as signaling molecules via 
interactions with cell surface receptors, including integrins (314).   Because of the 
multi-faceted roles of many ECM molecules, any single change in the 
extracellular matrix can trigger a cascade of dependent changes that influence 
the composition and properties of the ECM.  For example, biglycan serves as a 
structural component which regulates collagen fiber assembly but upon release 
from the matrix by can serve as a signaling molecule binding to TLR4 receptors 
(315).   
In the current study, the individual and combined effects of two 
experimental exposures (ethanol and LPS) on the hepatic matrisome were 
determined.  The rationale for selecting LPS is that it induces a robust 
inflammatory response in the liver.  Exposure of the liver to low levels of LPS is 
common and occurs through multiple means, including both acute and chronic 
alcohol consumption (316).  Whereas inflammatory responses triggered by small 
doses of LPS are typically non-injurious, other stresses can synergistically 
enhance the hepatotoxic response to LPS.  Indeed, in addition to increasing 
circulating LPS, ethanol also enhances inflammation and liver damage caused by 
acute LPS exposure (71, 170).  This ‘2-hit’ paradigm is a common factor in fatty 
liver diseases (34).  The results here demonstrate that the hepatic matrisome 
responded dynamically to both stresses, not only increasing the net amount of 
protein associated with the matrisome, but also differentially changed the 
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amounts (Figure 5.5) and likely the composition (Figure 5.3) of the proteins 
found.   
This study was able to validate changes in the hepatic matrisome that 
have been reported previously after LPS and/or ethanol exposure.  Indeed, this 
work validated that the fibrin(ogen) ECM is dramatically altered by LPS and 
enhanced by the combination of LPS + ethanol.  In the current study, LPS 
exposure caused a nearly 14-fold increase in the fibrinogen gamma chain in the 
GnHCl extract.  Additionally, both LPS and ethanol caused fibrinogen chains to 
appear in the NaCl and SDS extracts, suggesting an increased rate of turn-over 
of this ECM component.  The fibrin(ogen) gamma chain is a major component of 
fibrin clots which form upon cleavage of the fibrinogen gamma chain, causing its 
polymerization into insoluble fibrin fibers (317).  Therefore, the localization of this 
robust increase in fibrinogen gamma chain in the GnHCl fractions suggests that 
there was an increase in fibrin(ogen) gamma chain polymerization into a less-
soluble and more highly cross-linked form.  Furthermore, the combination of LPS 
+ ethanol resulted in presence of the fibrin(ogen) gamma chain in the insoluble 
pellet, which suggests additional modifications that increased insolubility (e.g., 
crosslinking).  LPS also caused the appearance of serum amyloid A-1 and A-2 
(SAA1 and SAA2) proteins, which are acute phase proteins whose production 
and secretion by hepatocytes is increased by LPS (318, 319).  In fact, LPS 
administration resulted in the presence of or increased the levels of several other 
acute phase proteins including haptoglobin, complement C, and ceruloplasmin, 
all of which are known to be increased in liver by LPS administration (320-322). 
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Proteomic analysis of liver tissue from animals exposed to chronic ethanol 
exposure also validated changes that others have shown to be caused by 
ethanol.  Previous studies have shown that ethanol exposure enhances 
fibronectin expression and deposition prior to the onset of fibrosis (28).  In this 
model of alcoholic steatohepatitis, we found that fibronectin expression was 
increased by nearly 2-fold in the GnHCl extract compared to control livers.  
Additionally, ethanol exposure increased the level of collagen 1α1, which has 
previously been shown to be increased in patients (323) and in animal models of 
alcoholic steatohepatitis (324).  Recent studies have also implicated the high-
mobility group protein B1 as a contributor to ALD and have shown that 
expression is increased in both the liver and serum after alcohol exposure (325).  
In our study, HMGB1 was increased in the NaCl fraction by 2-fold.   
Expression of several other matrix proteins were altered by chronic ethanol 
exposure.  For example, vitronectin levels were increased in the GnHCl extracts 
of ethanol-treated liver.  The extracellular glycoprotein vitronectin has previously 
been linked to hepatic fibrosis.  Indeed, end-stage hepatic fibrosis is 
characterized by decreased circulating levels of vitronectin due to decrease in 
hepatic function and an increase in vitronectin deposition locally in the liver (326, 
327).  The findings of this study suggest that more subtle changes in vitronectin 
expression occur prior to the onset of fibrosis and hepatic decompensation.  
Ethanol also resulted in the appearance of galectin-1.  Galectin-1 is 
glycosaminoglycan-binding lectin (328), which has been associated with cell 
proliferation and adhesion through modulation of glycoprotein crosslinking.  
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Galectin-1 may also play a role in hepatic inflammation and fibrinogenesis (329).  
For example, galectin-1 has been shown to be protective against experimental 
inflammatory liver injury (330).  This role may be in contrast to later stages of 
liver disease that correlate increased galectin-1 secretion from activated HSCs in 
hepatic fibrosis (331, 332).  Although additional studies will be required to 
validate functional changes in these proteins after alcohol exposure, these data 
suggest that ethanol is likely contributing to a myriad of changes in the 
extracellular matrix composition, many of which have not yet been fully 
investigated. 
Changes in expression of protease and protease inhibitors can also 
contribute to inflammatory liver injury and fibrogenesis.  In the current study, a 
number of matrix-associated proteases were present in the GnHCl extract of 
ethanol-exposed liver including plasmin(ogen), antithrombin III, dipeptidyl 
peptidase, and alpha-1-antitrypsin.  Plasmin(ogen) is a well-known serine 
protease which degrades fibrin into fibrin degradation products and is tightly 
regulated by a series of activators (urokinase and tissue-type plasminogen 
activators) and inhibitors (i.e. plasminogen-activator inhibitor 1; PAI-1).  In this 
study, both ethanol and LPS resulted in the presence of plasminogen in the 
GnHCl extract, suggesting that plasmin(ogen) was tightly associated with the 
ECM after either exposure.  LPS also resulted in the presence of protease 
inhibitors, such as serpine B5 (maspin) and PAI-1.  Several other proteases and 
protease inhibitors that may be critical for ECM homeostasis [e.g., transthyretin, 
phosphatidylethanolamin-binding protein-1 (PEBP1), and serine protease 
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inhibitor A2K] increased in response to ethanol and/or LPS.  These data support 
the notion that transitional remodeling of the hepatic matrisome is likely 
bidirectional and driven by both increased secretion of matrix proteins as well as 
changes in ECM degradation.   
As mentioned above, ethanol is well-known to synergize liver damage caused 
by LPS exposure.  In the current study, we found that the combination of ethanol 
and LPS resulted in unique changes to the hepatic matrisome compared to either 
ethanol or LPS alone.  Indeed, fibronectin and biglycan expression were all 
differentially increase by co-exposure.  Fibronectin accumulation caused by 
ethanol may contribute to hepatic inflammation via stimulation of KCs (308).  
Biglycan expression was also dramatically increased by the combination of 
ethanol + LPS.  Research suggests that biglycan may play a role in fibrotic liver 
disease (315, 333).  This small proteoglycan was first recognized as a structural 
component and signaling molecule in the ECM due to its association with 
collagen fibrils and its role in collagen fiber organization (334, 335).  In addition to 
its structural role, biglycan has been implicated in inflammation by retaining pro-
inflammatory cytokines including TNFα and TGFβ (336) and activating TLR4 
signaling (337); interestingly, in order to contribute to the inflammatory response, 
biglycan must be released from the collagens of the ECM by one of several 
MMPs (338).  Areas with increased bigylcan expression have also been 
associated with increased inflammatory cell migration (339).  These data suggest 
that biglycan expression may be increased in pre-fibrotic stages of liver disease.  
In contrast, the combination of ethanol and LPS resulted in a synergistic 
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decrease in the serine protease inhibitor phosphatidylethanolamine-binding 
protein-1 (PEBP1).  This enzyme has been shown to inhibit trypsin-like serine 
proteases including thrombin, but not trypsin or tissue-type plasminogen activator 
(296).  Multiple studies have identified PEBP1 as a critical player in metastasis 
(340), and have defined it as a metastasis suppressor gene (MSG) (341).  
Additional studies which implicate a role for PEBP1 in inhibition of NFκB (342), a 
well-recognized player in hepatic inflammation (343) further support a potential 
role for PEBP1 in inflammatory liver injury.  It is likely that other changes in the 
ECM previously undetermined may also contribute to hepatic inflammation and 
injury.   
In summary, an extraction method to enrich the hepatic ECM was 
developed and characterized.  The results demonstrate that the hepatic 
matrisome responds dynamically to both acute (LPS) and chronic (ethanol) 
stresses, long before more dramatic fibrotic changes to the liver.  It is likely that 
these transitional changes to the hepatic ECM contribute, at least in part, to the 
pathologic responses to these stresses.  It is also interesting that several ECM 
proteins responded similarly to both stresses, suggesting a common mechanism 
in both models.  Nevertheless, there were responses that were unique to the 
individual and combined effects.  These results therefore also serve as a 








DISCUSSION AND CONCLUSIONS 
 
A. Restatement of goals and questions 
The overall goal of the work described in this dissertation was to further 
elucidate the role of ECM remodeling in liver injury and the potential role of such 
changes on the pathology of other organs, such as the lung.  The experiments in 
Chapter III were performed to identify the potential role of gut dysbiosis in driving 
fibrin accumulation and liver injury in a model of enhanced fatty liver disease 
caused by the combination of HFD and arsenic. Chapter IV aimed to characterize 
a model of concomitant liver and lung injury in the context of chronic alcohol 
exposure that will allow further investigation of parallel and interdependent 
mechanisms of injury in these two organs, including transitional tissue 
remodeling.  Finally, Chapter V of this dissertation describes a new method of 
protein extraction which can be used for analysis of the extracellular matrix 
proteome.  Together, these studies shed new insight into the complex 








B. Major findings of this dissertation 
1. Dysbiosis contributes to hepatic sensitization and transitional tissue 
remodeling during NAFLD 
Previous studies from this group have shown that coexposure to low 
concentrations of arsenic and high-fat diet (HFD) enhanced liver injury and 
inflammation (98); importantly, these effects of arsenic correlated with an 
increase in proinflammatory fibrin ECM deposition.  However, whether enhanced 
hepatic injury in this model was due to interactions between arsenic and HFD 
locally in the liver or distally in the gut was unclear.  Therefore, the study 
described in Chapter III was designed to identify changes in the gut microbiome 
after concomitant HFD and arsenic exposure and to test the therapeutic potential 
of the prebiotic oligofructose (OFC) in this model; a major endpoint was whether 
or not this intervention would blunt the increase in fibrin ECM deposition caused 
by the combination of arsenic and HFD. 
Changes in the gut microbiome caused by HFD, as described in Chapter III 
support the link between HFD and dysbiosis previously demonstrated by others 
(78, 134).  Additionally, this study found that arsenic alone impacted the gut 
microbiome, leading to a net loss of commensal bacteria and expansion of the 
population of Gram negative bacteria.  Increases in Gram negative bacteria, 
which harbor a lipopolysaccharide wall, can contribute to endotoxemia and have 
been linked to liver injury (344, 345).  Therefore, the increase in Gram negative 
bacteria caused by arsenic may contribute to liver injury by enhancing HFD-
induced endotoxemia.  Another potential mechanism of enhanced injury may be 
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‘upstream’ of arsenic exposure.  For instance, HFD-induced steatosis and 
endotoxemia may sensitize the liver to otherwise innocuous levels of arsenic.  
HFD has previously been shown to sensitize the liver to injury by other factors, 
including LPS (145, 146).   
The work presented in Chapter III demonstrated a protective effect of OFC.  
Protection conferred by OFC was evidenced by a reduction of liver steatosis, 
fibrin ECM deposition and inflammation that is normally seen with HFD-feeding 
and a prevention of expansion of Gram negative bacteria caused by arsenic 
exposure, coupled with an expansion of potentially protective bacterial 
populations.  Protection against enhanced liver injury that was conferred by OFC 
is likely mediated by both direct effects on the microbiome as well as potentially 
indirect effects on hepatic sensitization.  For example, protection against 
increases in Gram negative bacteria, which can contribute to endotoxemia, may 
confer protection against liver injury.  Indeed, Adachi and colleagues 
demonstrated that depletion of Gram negative bacteria by enteral antibiotic 
administration protected against endotoxemia and liver injury caused by alcohol 
exposure (344).  Additionally, OFC has been shown to protect against HFD-
induced endotoxemia (80).  In agreement with this previous work, we found that 
OFC protects against steatosis caused by HFD-feeding to animals.  Steatosis 
and endotoxemia are two factors known to sensitize the liver to injury (34, 35).   
Therefore, protection against these changes by OFC feeding may diminish HFD-
induced hepatic sensitization and, ultimately, protect against increased sensitivity 
to arsenic toxicity.   
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It is hypothesized that the enhanced HFD-induced liver injury caused by 
arsenic exposure is mediated at least in part via deposition of fibrin ECM.  This 
hypothesis is supported by previously established proinflammatory effects of 
fibrin ECM in liver (29), as well as mechanisms hypothesized to be involved in 
the atherogenic effects of arsenic in the vasculature (346).  Here, this enhanced 
fibrin accumulation caused by arsenic was almost completely blunted by OFC 
administration.  These data support a role for transitional matrix remodeling in the 
setting of arsenic hepatotoxicity.  Fibrin ECM accumulation in the liver can be 
mediated via an increase in deposition (via activation of the coagulation 
cascade), and/or via a decrease in degradation (i.e., fibrinolysis) caused by PAI-1 
induction (29).  In the work presented here, PAI-1 expression was significantly 
increased by the combination of arsenic and HFD.  The implications of potential 
crosstalk between transitional tissue remodeling in the setting of fatty liver 
disease is a focus of future work in this laboratory.  The results of the current 
study lend weight-of-evidence that transitional changes in the hepatic ECM play 
a unifying role in the initiation and/or progression of fatty liver disease, be it from 
alcohol or from diet (HFD).   
2. Chronic ethanol exposure causes unique pro-inflammatory changes 
in the liver and lung after systemic LPS administration 
Chapter IV of this dissertation aimed to characterize a model of concomitant 
liver and lung injury in the context of chronic ethanol exposure and to establish a 
potential link between injury of these two organs.  As mentioned in the 
Introduction, work by this group and that of the Roman laboratory has been 
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pursuing in parallel the role of transitional matrix changes in inflammatory liver 
and lung injury.  Whereas the detrimental effects of chronic alcohol exposure on 
the liver and lung are well established separately, potential links between the two 
are less well characterized.  However, clinical studies have suggested a potential 
interaction between the liver and lung; for example, hepatic cirrhosis increases 
mortality due to acute lung injury to nearly 100% (152).  Additionally, an 
experimental model of endotoxic shock has shown that LPS-induced lung 
damage required interaction with the liver (84).  Therefore, the damage to liver 
and lung caused by transitional ECM changes may not only be parallel 
pathologic responses, but interdependent mechanisms.  Elucidating these 
mechanisms therefore offers the possibility to develop novel therapeutic 
approaches.  Prior to these critical experiments being performed, the model 
needed to be developed. 
In the work presented here, ethanol preexposure enhanced LPS-induced 
injury and inflammation in both the liver and the lung.  Interestingly, ethanol 
preexposure caused changes to the mRNA expression of inflammatory cytokines 
that was unique to each organ.  For example, ethanol preexposure caused a 
significant increase in TNFα mRNA expression in the liver which correlated with a 
significant increase in plasma levels of TNFα in animals exposed to ethanol and 
LPS.  In contrast, ethanol preexposure did not alter TNFα expression in LPS-
exposed lungs.  Ethanol preexposure did, however, enhance mRNA expression 
of the TNFα sensitive genes MIP-2 and KC in the lung.  Both MIP-2 and KC have 
been shown to contribute to pulmonary injury caused by LPS (154, 178) and 
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blocking TNFα expression has been shown to protect against increases MIP-2 
and KC in the lung (88).  To address the potential role of TNFα in driving 
pulmonary MIP-2 levels, we used a TNFα binding antibody, etanercept, in an 
attempt to block enhanced pulmonary injury caused by ethanol exposure.  As 
expected, etanercept blunted plasma TNFα levels.  Etanercept also protected 
against enhanced pulmonary mRNA expression of MIP-2 and KC in lung and 
also caused a significant decrease in MIP-2 levels in the BALF.  Attenuation of 
the increase in MIP-2 correlated with protection against pulmonary injury, as 
indicated by pulmonary pathology.  These findings suggest that enhanced 
systemic TNFα caused by ethanol preexposure may contribute to pulmonary 
injury.  Additionally, Kono and colleagues have suggested that KC-derived 
inflammatory mediators, including TNFα, contribute to pulmonary injury after 
systemic LPS exposure (347).  Therefore future studies by our lab should aim to 
elucidate the potential contribution of hepatic-derived TNFα using models that 
specifically block the release of TNFα from the liver.  This work also lays the 
foundation to investigate the key role of ECM changes in both organs and their 
independence in pathology. 
3. The hepatic matrisome undergoes dynamic changes after ethanol 
and LPS exposure. 
The first 2 studies build on our understanding of the role of transitional ECM 
changes in liver damage (Chapter III) and develop a new model to leverage 
these questions in the interplay between liver and lung damage (Chapter IV); 
however, a limitation of previous studies is that they generally investigated 
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changes in one ECM protein at a time (e.g., fibrin; Chapter III) and ignore 
structural changes that may occur with altered ECM protein turnover.  Although 
the role of the ECM is well established in the setting of chronic liver injury and 
alcoholic liver disease (ALD), the study of the hepatic ECM changes has been 
focused primarily on dramatic changes in the ECM during fibrogenesis and 
specifically the contribution of collagen ECM in driving this process.  However, 
recent studies have shown that multiple ECM proteins contribute to fibrogenesis 
(48), and that the hepatic ECM is altered prior to fibrogenesis (28).  Therefore the 
goal of Chapter V was to adapt a sequential protein extraction method developed 
for cardiovascular research (95-97) to facilitate LC-MS analysis of global 
changes in the hepatic matrisome after chronic alcohol exposure.  Such an 
approach could discover new proteins that are changed by insults.  Furthermore, 
the sequential extraction methods yield new insight into potential changes in 
turnover. 
The 3-step protein extraction described in Chapter V allowed efficient 
extraction of the hepatic ECM proteome into four distinct extracts.  These 
consisted of loosely-associated ECM proteins (NaCl extract), intracellular and 
membrane-associated proteins (SDS extract), tightly bound ECM proteins 
(GnHCl extract), and highly insoluble ECM components (the remaining pellet).  A 
total of 147 extracellular proteins were identified in this study (Table 5.1).  
Qualitative analysis of the ECM proteins in each fraction demonstrated that both 
ethanol and LPS caused dynamic changes in the ECM.  While neither ethanol 
nor LPS changed the general pattern of proteins found in the various extracts, 
 133 
 
both tended to increase the number of ECM proteins.  Despite no changes in the 
general pattern of proteins, there were 22 proteins and 14 proteins whose 
presence was unique to ethanol and LPS exposure, respectively.  These unique 
subsets of proteins may play critical roles in the hepatic response to stress.  
There were also quantitative changes in protein abundance caused by ethanol or 
LPS that may impact function.  Interestingly, the combination of ethanol and LPS 
caused both qualitative and quantitative changes in the hepatic ECM.  Analysis 
of these global changes in the hepatic matrisome may identify new key players in 
the development of liver injury, the roles of which can be validated in future 
studies.  Furthermore, analysis of changes specific to chronic ethanol exposure 
may reveal new insights into the mechanisms of liver sensitization caused by 
alcohol, thus leading to potential therapeutic targets.  Most importantly, this work 
emphasizes dynamism in the hepatic ECM proteome responses to stress that 
opens a new critical area of future research.  This work also lays the foundation 
for future studies, such as investigating the interactive changes between the 
hepatic and pulmonary ECM proteome, using the model established in Chapter 
IV. 
 
C. Significance of new findings 
The findings of Chapter III have identified dysbiosis as a potential 
mechanisms by which HFD feeding may predispose individuals to increased 
toxicity from environmental toxicant, such as arsenic.  While the levels of arsenic 
exposure to most Americans is typically considered sub-toxic, data presented 
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here suggest that other factors which alter the gut microbiome, like HFD, may 
sensitize the liver to injury by otherwise innocuous exposures.  Such interactions 
are becoming more relevant as the incidence of NAFLD continues to increase 
both nationally as well as globally.  Indeed, the estimated prevalence of NAFLD 
in the US may be as high as 19% (39), however only a minority of these 
individuals will progress to later stages of disease (40-42).  A better 
understanding of the interactions that occur between diet and environmental 
exposures will offer new insights into potential risk factors for the development of 
NAFLD in the human population and allow better identification of at-risk 
populations.   
The role of inter-organ crosstalk during disease states such as multi-organ 
failure and sepsis is well established but mechanisms underlying these 
interactions can be very complex and largely remain incompletely understood.  
Chapter IV characterized a model of concomitant liver and lung injury in the 
setting of chronic alcohol exposure.  Characterization of this model will bring 
attention to the parallel mechanisms of injury in these two organs as well as the 
potential for extensive interdependence between them.  Better understanding of 
the contribution of hepatic-derived mediators in the increased susceptibility to 
lung injury after alcohol exposure may provide new insights into the mechanisms 
underlying dysregulated immune response and tissue remodeling in the lung.    
Chapter V describes a new method of hepatic matrisome extraction and 
analysis.  Implementation of this new method will allow identification of new 
players in fatty liver disease paradigm.  Furthermore, adaptation of this method 
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will allow analysis of global changes in the extracellular matrix in other models of 
liver injury (i.e., NAFLD) and in other organs (i.e., the lung).  Identifying new 
targets in disease progression could potentially be beneficial for individuals with 
early stages of liver disease by offering a means to prevent progression to later 
stages of disease.   
 
D. Strengths and Weaknesses 
1. Strengths 
There are several strengths of this dissertation.  One such strength is that 
it identifies gut dysbiosis as a new potential mechanism mediating interaction 
between diet-induced liver disease and environmental toxicants (i.e., arsenic 
exposure).  The findings of this study provide additional support for the use of 
prebiotics as a potential therapeutic for early stages of liver disease, and 
potentially as a prophylactic therapy to protect against environmental liver 
disease.  This work also describes an initial characterization of a new model of 
concomitant liver and lung injury after chronic alcohol exposure.  
Characterization of this new model will allow a better understanding of how 
alcohol affects the entire person (or mouse) rather than an individual organ.  Use 
of this model may also provide new insights into why some lung-specific 
approaches to the study and treatment of pulmonary injury after alcohol exposure 
are not completely effective and that systemic therapies (e.g., etanercept) may 
confer new avenues of treatment.  
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Additionally, a new method of protein extraction has been validated for 
use with liver tissue, effectively allowing the analysis of low-expressing and 
highly insoluble hepatic ECM proteins.  LC-MS analysis of these extracts has 
opened the door for a discovery-based research approach that can help to 
expand the foundation of new hypothesis-driven studies and possibly increase 
the identification of new therapeutic targets.  Importantly, this work also 
demonstrates that the hepatic ECM proteome responds dynamically to stress.  
Whereas such dynamism for the ECM is well understood in other organs and 
systems, most work in the liver has focused predominantly on hepatic fibrosis. 
Another strength of this work is the use of whole animal models.  Most of 
the experiments described here were performed in vivo.  As mentioned 
previously, liver disease and the effects of alcohol use are complex phenomena 
which are not limited to a single organ or cell type.  The use of in vivo models in 
the experiments described here allowed the study of interactions between 
multiple organs, including the gut, liver, and lung.  Indeed, all of the questions 
that were addressed here likely could not be sufficiently recapitulated in a simpler 
model system (e.g., cultured cells). 
 
2. Weaknesses 
Although the use of animal models of disease is a strength, it is also a 
potential source of complexity.  There is almost always an inverse relationship 
between the validity of the model and the degree to which the model can be 
controlled and therefore how certain our conclusions may be.  Therefore, 
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although in vivo is a more valid approach than simpler models, the ‘black box’ is 
also much larger.  Furthermore, although in vivo research is preferred for the 
study of inter-organ phenomena, no animal model can completely recapitulate 
the human condition.  Indeed, there is currently no rodent model that exactly 
represents the progression of fatty liver disease, increased susceptibility to lung 
injury, or the typical human microbiome.  It is therefore possible that the 
observed changes in the microbiome or mastrisome are unique to the species 
tested and have little direct relevance to human beings. 
The work presented here identified the microbiome as a site for interaction 
between a HFD and the environmental contaminant arsenic.  This study focused 
on changes in the microbiome caused by arsenic, HFD and OFC administration 
rather than the potential effects that the microbiome might be having on these 
parameters.  Lu et al have shown that arsenic-induced dysbiosis does cause 
functional changes in the gut metabolome (2).  Future studies will be necessary 
to pare out additional, bidirectional changes in the microbiome and arsenic 
metabolism.   
One weakness of this project is the use of systemic administration of 
etanercept to block TNFα investigate the potential interaction between liver and 
lung injury.  Whereas the liver is known to contribute to enhanced systemic levels 
of pro-inflammatory cytokines, including TNFα, systemic etanercept binds TNFα, 
regardless of source.  Studies that aim to identify the role of hepatic-derived 
mediators in the development of lung injury will require an experimental model 
which allows specific blockage of liver-derived TNFα.   
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The experiments described in Chapter V identified changes in the hepatic 
matrisome after alcohol and LPS exposure.  Unfortunately, due to the cost of LC-
MS analysis, study samples were pooled prior to LC-MS.  This is a significant 
weakness of this study as qualitative changes in protein expression could have 
been driven by a single sample.  Future studies would be strengthened by 
analysis of individual samples as separate runs, or via ‘multiplexing’ the samples 
with protein tagging.  Additionally, the experiments described herein did not 
determine the functional significance of the changes in the ECM.  Future studies 
will be required to validate that changes in the matrisome caused by LPS and/or 
ethanol cause functional change in vivo and in vitro.   
 
E. Future Directions 
While the experiments described in this dissertation answered specific gaps 
in our knowledge of ECM remodeling, it has also created new questions that will 
need to be addressed in future studies.  Some of these are discussed below. 
1. Does HFD-induced dysbiosis change arsenic metabolism and/or 
absorption? 
Because the experiments described in Chapter III were largely concerned 
with the effect of arsenic, HFD, and OFC on the gut microbiome, the bidirectional 
effects of dysbiosis on arsenic metabolism and absorption were not determined.  
Lu and colleagues have previously shown that higher levels of arsenic can cause 
changes in the gut metabolome (124) and that dysbiosis caused by bacterial 
infection altered arsenic metabolism (348).  In vitro studies have also shown that 
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the bacteria of both the mouse and human gut can metabolize arsenic in vitro 
(141-143) .  Such findings suggest that dysbiosis caused by HFD could cause 
dramatic changes in arsenic metabolism.  An important endpoint of future studies 
would include hepatic levels of arsenic and arsenic metabolites.  Indeed, 
increased levels of arsenic in the liver of HFD-fed mice may contribute to 
enhanced liver injury in the model presented here.  On a related note, it would be 
interesting to determine if arsenic has global effects on the hepatic matrisome; 
this question is especially valid, since previous work by others has shown that 
very low concentrations of arsenic cause hepatic endothelial remodeling (46)  
Work by others in our group are pursuing these questions using the ECM 
proteomic approach developed in Chapter V. 
 
2. Does liver-derived TNFα contribute to the alcoholic lung phenotype? 
In the experiments described in Chapter IV, etanercept was used to identify 
the potential role of extra-pulmonary TNFα in driving lung inflammation.  While 
studies have shown that hepatic Kupffer cells are responsible for ~90% of the 
increase in plasma TNFα caused by LPS (172) the role of liver-derived TNFα 
needs to be determined using a model in which one can specifically block TNFα 
release from the liver.  One approach to this problem would be to use Kupffer cell 
chimeric mice to impair production of tumor necrosis factor α converting enzyme 
(TACE) in Kupffer cells.  TACE is an enzyme required for cleavage and systemic 
release of TNFα into the blood.  The use of such chimeras would target TACE 
deficiency to the Kupffer cells and thereby block hepatic TNFα signaling.  These 
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studies would identify the contribution of hepatic TNFα in the lung alterations 
caused by chronic alcohol exposure.  The protocol for generating the chimeras to 
perform these studies are currently being optimized. 
 
3. What are the functional effects of changes in the hepatic matrisome 
of LPS and ethanol-exposed livers? 
The method described in Chapter V identified dynamic changes in the hepatic 
matrisome after ethanol and/or LPS exposure. However, the functional effects of 
these changes has yet to be determined.  Others have shown that the 
extracellular matrix from decellularized tissues can be solubilized and used to 
coat cell culture plates where it serves as a substratum for cells in vitro (349).  By 
using plates coated with the ECM of animals exposed to ethanol or LPS, the 
functional effects of changes in the ECM composition on cell migration activation 
could be determined.   In vivo experiments using inhibitors that block the 
interactions between the ECM and cell surface receptors may also provide 
insight into the functional effects of changes in the hepatic matrisome after 
alcohol and LPS exposure.  Indeed, previous studies from our group have shown 
that the integrin inhibitor CycloRGDfV can protect against enhanced liver injury 
and inflammation caused by acute ethanol exposure and LPS (350). 
 
4. What changes does alcohol exposure cause to the lung matrisome?  
Experimental alcohol exposure has been shown to contribute to the alcoholic 
lung phenotype which is characterized by oxidative stress (58), dysregulated 
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immune response (186, 189), and tissue remodeling of the lung (59, 351, 352).  
Indeed, studies have shown that alcohol exposure increases the expression of 
fibronectin by pulmonary fibroblasts (68).  Additional studies have shown that 
ethanol also causes increased expression and activity of matrix 
metalloproteinases (MMPs) (62).   Furthermore, the fibronectin-rich matrix 
produced by alcohol-exposed alveolar macrophages appears to contribute to 
functional changes in the lung after alcohol exposure, including monocyte 
activation (353).  A discovery-based method, such as that described in Chapter 
V, would allow for analysis of global changes to the pulmonary matrisome after 
alcohol exposure.   Furthermore, identification of new players in transitional 
tissue remodeling in the lung would expand the foundation for new hypothesis-
driven studies investigating the role of ECM proteins in alcohol-related 
susceptibility to acute lung injury. 
 
Summary and Conclusions 
 
 
The overall goal of the work described in this dissertation was to build upon the 
unifying hypothesis that changes in the ECM contributes to hepatic pathology as 
well as pathology in other organs, such as the lung.  The experiments described 
in Chapter III further support the critical role of fibrin deposition in the 
development of steatohepatitis and the potential contribution of arsenic exposure 
on hepatic tissue remodeling. These findings suggest that future studies by our 
group should include investigation of changes in the hepatic extracellular matrix 
in models of non-alcoholic liver disease.   Chapter IV characterized a new model 
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of concomitant liver and lung injury in the context of chronic alcohol exposure 
that will lay the foundation for testing the hypothesis that liver injury is critical to 
transitional ECM remodeling in the lung.   Finally, Chapter V described a new 
proteomic strategy for characterizing the extracellular proteome which will allow 
identification of new players in transitional tissue remodeling in the liver and 
potentially the lung in future experiments.  Taken together, this work has shed 
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LefSe Linear effect size 
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